Research Protocols - OPS Peptide Science

Peptide Education, Product Pillars, Research Protocols

Epitalon: Complete Research Guide to the Telomerase Peptide

Posted on June 1, 2026June 1, 2026 by admin

01
Jun

Research Use Only Notice: Epitalon is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

Epitalon is a four-amino-acid synthetic peptide that has become the most cited research compound in telomere biology and pineal gland aging research. Developed from research on pineal gland extracts (epithalamin), Epitalon has been the focal compound of Russian longevity research programs for decades and is increasingly studied by Western research groups. Published literature documents Epitalon’s effects on telomerase activation, telomere length, melatonin restoration, and lifespan extension across multiple animal aging models. This complete guide from the chemistry team at OPS Peptide Science walks through what Epitalon is, how the pineal and telomere mechanisms work, and where it sits in the broader longevity peptide catalog.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is Epitalon?

Epitalon is a synthetic peptide derived from research on epithalamin — a complex peptide extract from bovine pineal glands. Russian research programs identified the active four-amino-acid sequence within epithalamin and synthesized it as a discrete compound, naming it Epitalon. The compound has been studied primarily through Russian and Ukrainian research programs spanning several decades, with growing international research interest.

Key facts about Epitalon:

Chemical class — 4-amino-acid synthetic peptide (tetrapeptide)
Molecular weight — approximately 390 Da
Sequence — Ala-Glu-Asp-Gly (AEDG)
Half-life — short, approximately 30 minutes
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
Origin — Russian longevity research programs, primarily Vladimir Khavinson’s lab at St. Petersburg Institute of Bioregulation and Gerontology
Research focus — telomere biology, pineal gland aging, melatonin regulation, lifespan research

Epitalon’s small size and simple sequence belie its research interest — much of modern peptide longevity research has been built around questions raised by Russian Epitalon studies. The compound has become a focal point in telomere biology research because it is one of the few small peptides documented to influence telomerase activity in research models.

Epitalon Structure and Chemistry

Epitalon’s structure is remarkably simple by peptide research standards:

Only four amino acids — alanine, glutamic acid, aspartic acid, glycine in sequence
Acidic character — two acidic residues (glutamic and aspartic acid) give the peptide a negative charge at physiological pH
No modifications — no acetylation, no fatty acid chains, no D-amino acids; the peptide is the natural sequence with no engineering for stability
Highly water-soluble — the small size and acidic residues make Epitalon readily soluble in aqueous solutions

The simplicity of Epitalon’s structure is part of why it has been so widely studied — it is straightforward to synthesize, easy to handle in laboratory contexts, and stable enough for reliable research protocols. The downside is the short half-life — without stability modifications, Epitalon clears rapidly from circulation, requiring frequent dosing in research protocols.

How Epitalon Works in Research (Mechanism)

Epitalon’s mechanism is unusual for a research peptide — it doesn’t bind a known cell-surface receptor in the way most peptides do. Instead, research has documented effects through several converging pathways:

Telomerase activation — published research documents Epitalon-induced telomerase enzyme activity in cell culture studies, with downstream effects on telomere length
Pineal gland modulation — research suggests Epitalon acts as a peptide regulator of pineal gland function, affecting melatonin synthesis patterns
Gene expression effects — research has documented Epitalon modulation of genes involved in aging biology, telomere maintenance, and circadian regulation
Direct DNA-binding hypothesis — some research proposes that small peptides like Epitalon may interact directly with regulatory DNA regions, though this mechanism remains debated
Antioxidant pathway engagement — research models have documented Epitalon effects on oxidative stress markers

The mechanism is incompletely characterized compared to many other research peptides. Russian research has documented effects more extensively than Western research has reproduced — though Western studies have confirmed portions of the findings, particularly on telomerase activity and gene expression in cell culture. The published Epitalon research literature on PubMed includes both the original Russian research base and growing international replications.

Epitalon Research Applications

Telomere Biology Research

The largest body of Epitalon research focuses on telomere biology — the protective caps at the ends of chromosomes that shorten with cell division and aging. Telomere shortening is a hallmark of cellular senescence and an established biomarker of biological aging. Epitalon’s documented effects on telomerase activity and telomere length make it a primary research tool in this area.

Pineal Gland & Melatonin Research

The pineal gland produces melatonin and regulates circadian biology. Pineal function declines with age, reflected in disrupted melatonin rhythms in older subjects. Research has documented Epitalon effects on restored melatonin patterns in aging research models.

Circadian Biology Research

Connected to the pineal mechanism, Epitalon research extends into circadian rhythm research — sleep-wake cycle regulation, seasonal biology, and circadian gene expression. Research has measured Epitalon effects on circadian markers in animal models.

Lifespan Research

Russian research has documented Epitalon-induced lifespan extension in animal aging models — rodents and other species. While these findings remain under continued investigation in Western research programs, they have positioned Epitalon as one of the few research peptides with published lifespan-extension data in animal studies.

Antioxidant Research

Research has measured Epitalon effects on cellular oxidative stress markers — reactive oxygen species levels, antioxidant enzyme activity, and lipid peroxidation. These effects connect Epitalon biology to broader aging research where oxidative damage accumulates with age.

Visual System Research

A smaller but documented research area on Epitalon effects in retinal biology, including age-related visual decline research models. The pineal-retinal connection through circadian biology provides the mechanistic basis for this research.

The Russian Research Heritage

Most of the Epitalon research base originates from Russian and Soviet-era research programs, particularly the work of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Key features of this research heritage:

Multi-decade research timeline — research spans from the 1970s pineal extract research through modern synthetic Epitalon studies
Large clinical research base — Russian clinical research has included hundreds of participants across various indications
Multiple aging models — research extends across rodent species, including longevity studies
Integration with broader peptide bioregulator research — Khavinson’s lab has studied dozens of short regulatory peptides; Epitalon is one of the most-studied of these

Western research has been slower to reproduce some of the Russian findings, partly due to language barriers and partly due to differences in research priorities. Modern Western research has been replicating portions of the findings — particularly on telomerase activity and gene expression — building a more globally distributed research base. The NIH research literature increasingly documents Epitalon studies as Western interest grows.

Epitalon vs Other Longevity Peptides

Brief comparison to other longevity research peptides:

Peptide	Primary Mechanism	Research Focus
Epitalon	Telomerase activation, pineal modulation	Telomere biology, lifespan, melatonin
MOTS-c	AMPK activation, mitochondrial-encoded	Metabolic, insulin sensitivity
SS-31	Cardiolipin binding, mitochondrial	Cardiac, neurodegeneration
GHK-Cu	Multi-pathway gene expression	Skin biology, broad aging

Each compound addresses different aspects of aging biology. Epitalon’s unique position is in telomere and pineal research — areas where few other research peptides have meaningful published activity. Research designs studying broad longevity often combine multiple compounds to address different aging mechanisms.

Epitalon Dosing in Research Models

Research dosing of Epitalon follows patterns established in the Russian research literature:

Subcutaneous administration — standard route in animal research
Daily or twice-daily dosing — the short 30-minute half-life supports frequent administration
Cycle-based protocols — 10-20 day cycles followed by washout periods are common in published research; some protocols use longer continuous dosing periods
Dose amounts — typically reported in mg per dose in clinical research; animal research uses mg/kg ranges
Study duration — many published Russian studies extend over months or years to capture lifespan and aging-related endpoints

Research protocols should reference published methodology for the specific research model. The cycle-based dosing pattern is particularly characteristic of Epitalon research — distinct from continuous dosing protocols used for many other research peptides.

Storage and Stability

Epitalon stability follows standard small-peptide patterns:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our companion guide on how long do peptides last at room temperature.

How to Identify Quality Research-Grade Epitalon

Epitalon’s small size and simple sequence make it relatively straightforward to synthesize cleanly. Quality criteria:

99%+ HPLC-MS verified purity — the simple structure should produce very clean synthesis with high purity
Per-lot Certificate of Analysis — each batch independently tested
Mass spectrometry identity confirmation — confirms molecular weight matches Epitalon (~390 Da)
Amino acid sequence verification — confirms AEDG sequence is correct
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every Epitalon vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity and identity before opening the vial.

Regulatory Status

Not FDA-approved — Epitalon has not completed US clinical trials for drug approval
Research-use only in the US — sold under research-use-only labeling for in-vitro and animal research
Used in Russian clinical research — substantial Russian clinical literature, though not US-approved
Not WADA-prohibited as of current updates
Not DEA-scheduled — no controlled substance status

For the complete legal framework around research peptides like Epitalon, see our detailed guide on are peptides illegal.

FAQ

What is Epitalon?

Epitalon is a four-amino-acid synthetic peptide (sequence Ala-Glu-Asp-Gly) derived from research on pineal gland extracts. It is the most-studied peptide in telomerase and telomere biology research, with documented effects on telomere length, pineal function, melatonin regulation, and lifespan in animal aging models.

Does Epitalon really lengthen telomeres?

Research has documented Epitalon activating telomerase in cell culture studies, with downstream effects on telomere length in some animal research models. The findings are most robust in cell culture; animal research data is more variable. Whether the effects translate to broader aging biology remains an active research question — the cell-level mechanism is established, but the systemic implications are still being characterized.

Is Epitalon FDA-approved?

No. Epitalon has not completed US clinical trials for drug approval. It is legally sold in the US as a research chemical for in-vitro and animal research under research-use-only labeling.

How is Epitalon dosed in research?

Research dosing varies by study design. Common patterns include subcutaneous administration, daily or twice-daily dosing (due to the short half-life), and cycle-based protocols of 10-20 days on followed by washout periods. Specific dosing should reference published methodology for the research model being used.

What’s the difference between Epitalon and other longevity peptides?

Epitalon’s primary research focus is telomere and pineal biology — areas where few other peptides have documented activity. MOTS-c addresses metabolic and insulin sensitivity. SS-31 addresses mitochondrial structure. GHK-Cu addresses skin and broad gene expression. Each compound addresses different aspects of aging biology, and many research designs combine compounds to cover multiple mechanisms.

Why is most Epitalon research Russian?

The compound was developed in Russian research programs, particularly Vladimir Khavinson’s lab in St. Petersburg. Decades of Russian research built the original literature base. Western research has been replicating portions of the findings as international interest grows, particularly on telomerase activity and gene expression mechanisms.

Where can I buy research-grade Epitalon?

Research-grade Epitalon is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and sequence verification. Browse the OPS Peptide Science catalog for verified research-grade Epitalon.

Epitalon occupies a unique position in the longevity peptide catalog — a small synthetic compound with substantial Russian research history and growing Western research interest. The combination of telomerase activity, pineal modulation, and documented lifespan effects in animal models makes Epitalon one of the most-cited research peptides in telomere biology and pineal aging research. For researchers studying telomere length, melatonin biology, or broad longevity endpoints, Epitalon remains a key compound in the modern research catalog.

For research-grade Epitalon backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: Feb 2026

Peptide Education, Product Pillars, Research Protocols

Thymosin Alpha-1: Complete Research Guide to the Immune-Modulating Peptide

Posted on June 1, 2026June 1, 2026 by admin

01
Jun

Research Use Only Notice: Thymosin Alpha-1 discussed in this article as a research compound is intended for in-vitro and animal research applications only. While Thymosin Alpha-1 has been approved for human therapeutic use in over 35 countries, it is not FDA-approved in the United States. Nothing in this article constitutes medical advice or guidance for human consumption.

Thymosin Alpha-1 — also written Tα1 — is a 28-amino-acid peptide derived from the thymus gland that has become one of the most clinically researched immune-modulating compounds in modern peptide science. Originally isolated from thymic tissue in the 1970s, Thymosin Alpha-1 is approved for therapeutic use in over 35 countries internationally for indications including hepatitis B, hepatitis C, immune reconstitution, and as an adjuvant in some cancer protocols. In the United States, it remains a research-grade compound under research-use-only labeling. This complete guide from the chemistry team at OPS Peptide Science walks through what Thymosin Alpha-1 is, how it modulates immune function, and where it sits in the broader research catalog.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from bovine thymus extracts and now produced synthetically. The thymus gland is the organ where T-cells mature, and Thymosin Alpha-1 is one of several thymic peptides involved in this process. Of the various thymic peptides identified in early research, Tα1 has become by far the most studied and the most clinically applied.

Key facts about Thymosin Alpha-1:

Chemical class — 28-amino-acid synthetic peptide derived from prothymosin alpha
Molecular weight — approximately 3108 Da
Sequence — Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN (N-terminally acetylated)
Half-life — approximately 2 hours
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
International brand name — Zadaxin (in countries where it is therapeutically approved)
Approved use in — 35+ countries internationally; not FDA-approved in the United States

Thymosin Alpha-1’s unusual regulatory position — therapeutically approved in dozens of countries but not in the US — gives the compound a uniquely robust clinical research base. Tens of thousands of patients have received Thymosin Alpha-1 in clinical settings worldwide, producing more documented human research data than most non-FDA-approved peptides in the research catalog.

Thymosin Alpha-1 Structure and Chemistry

Thymosin Alpha-1’s structure reflects its natural origin from prothymosin alpha (ProTα), a longer 113-amino-acid precursor protein. Key structural features:

Acetylated N-terminus — the N-terminal serine carries an acetyl modification, naturally present in mammalian-produced Tα1 and reproduced in synthetic versions
Highly conserved across species — the Tα1 sequence is identical in human, bovine, rat, and most mammalian sources
Acidic character — high content of glutamic and aspartic acid residues gives the peptide a strong negative charge at physiological pH
No disulfide bonds or complex modifications — relatively straightforward synthesis compared to many research peptides

The structural conservation across species is part of why Tα1 research data translates relatively well between animal models and human applications — the molecule is essentially identical across organisms.

How Thymosin Alpha-1 Works in Research (Mechanism)

The Thymosin Alpha-1 mechanism involves multiple immune system pathways. Research has documented effects on several immune cell types:

T-cell maturation enhancement — promotes maturation of T-cell precursors in research models, particularly relevant in immunosenescence and post-immunosuppression research
Dendritic cell modulation — affects dendritic cell function and antigen presentation, key steps in initiating adaptive immune responses
Toll-Like Receptor (TLR) signaling — binds and modulates TLR2 and TLR9 signaling pathways, influencing innate immune responses
Th1/Th2 balance modulation — promotes Th1-skewed responses in research models, useful for studies of cellular immunity
NK cell activity enhancement — research has documented increased natural killer cell activity
Cytokine modulation — measurable effects on IFN-γ, IL-2, and other immune signaling molecules

Unlike many research peptides with single-pathway mechanisms, Thymosin Alpha-1 acts as a broad immune modulator — engaging multiple receptors and immune cell types to support coordinated immune function. This multi-pathway activity is part of why the compound has applications across so many research areas (hepatitis, sepsis, vaccine adjuvant, post-chemotherapy immune recovery). The published Thymosin Alpha-1 immune research literature on PubMed documents these mechanisms across thousands of studies.

Thymosin Alpha-1 Research Applications

Hepatitis Research

The largest body of Thymosin Alpha-1 clinical research focuses on hepatitis B and hepatitis C — both viral infections where the immune response to the virus determines outcomes. Tα1 has been studied in hundreds of clinical trials in international research, often combined with interferon-based therapies. This research base is what drove the compound’s therapeutic approval in countries with significant hepatitis burden.

Sepsis Research

Severe sepsis research has used Thymosin Alpha-1 to study immune dysregulation contributions to sepsis outcomes. Research has measured Tα1 effects on T-cell function, cytokine profiles, and survival markers in sepsis research models.

Cancer Adjuvant Research

Tα1 has been studied as an adjuvant in research investigating immune support during chemotherapy. The research focus is on immune reconstitution following chemotherapy-induced immunosuppression — measuring T-cell recovery, vaccination response, and infection susceptibility endpoints.

Vaccine Adjuvant Research

Tα1 enhances vaccine responses in research subjects with weakened immune systems. Research has documented improved vaccine seroconversion rates and antibody titer durability when Tα1 is co-administered with vaccines, particularly in elderly research populations and post-transplant patients.

Immune Recovery Research

Research on immune recovery following immunosuppression — whether from disease, medication, or surgical procedures — has used Tα1 to measure restoration of T-cell function and innate immune capacity. This research extends into aging-related immune decline (immunosenescence) and immune recovery in aging research models.

Infectious Disease Research

Beyond hepatitis, Tα1 research extends into broader infectious disease applications — from chronic viral infections to severe respiratory infection research. The immune-modulating mechanism has broad relevance across infection biology.

International Approval Status: A Unique Position

Thymosin Alpha-1’s regulatory status is unusual among research peptides. The compound is therapeutically approved for human use in over 35 countries — including China, Italy, South Korea, and many others — typically for hepatitis B and hepatitis C indications. This international approval base means:

Decades of clinical safety data — extensive post-marketing surveillance from approved uses
Established dosing protocols — international research has refined dosing patterns across multiple indications
Long-term tolerability documentation — broader data than most research-only peptides
Production scaled to pharmaceutical standards — synthesis protocols are well-established because of the therapeutic market

The compound has been included in the WHO essential medicines considerations for specific indications in some regions. Despite this international history, Thymosin Alpha-1 has not pursued or completed FDA approval in the United States. In the US, it remains a research chemical sold under research-use-only labeling.

Thymosin Alpha-1 Dosing in Research Models

Thymosin Alpha-1 dosing in published research follows patterns established by the international clinical experience:

Subcutaneous administration — standard route in both research and clinical contexts
Twice-weekly dosing — common protocol in chronic hepatitis research
Daily dosing — used in acute research applications and sepsis research
Cycle-based protocols — some research designs use 6-month cycles followed by evaluation periods
Dose amounts — typically 0.8-1.6 mg per dose in clinical research; animal research uses mg/kg dose ranges

The well-established dosing protocols from international clinical experience provide a stronger methodological foundation than is available for most non-FDA-approved peptides. Research protocols can reference both pre-clinical and clinical literature. For effect-timeline context, see our guide on how long does it take for peptides to work.

Storage and Stability

Thymosin Alpha-1 stability follows standard medium-sized peptide patterns:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our companion guide on how long do peptides last at room temperature.

How to Identify Quality Research-Grade Thymosin Alpha-1

Quality criteria for research-grade Thymosin Alpha-1:

99%+ HPLC-MS verified purity — synthesis of 28-amino-acid acetylated peptides requires careful purification
Per-lot Certificate of Analysis — each batch independently tested with full chromatographic profile
Mass spectrometry identity confirmation — confirms molecular weight matches Thymosin Alpha-1 (~3108 Da)
N-terminal acetylation verification — confirms the natural N-acetyl modification is present
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every Thymosin Alpha-1 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity, identity, and N-terminal acetylation before opening the vial.

Regulatory Status

Approved for therapeutic use in 35+ countries — hepatitis B and C primary indications, with broader regional approvals
Not FDA-approved in the United States — no equivalent prescription pathway in the US
Legal as research chemical in the US — sold under research-use-only labeling for in-vitro and animal research
Not WADA-prohibited as of current updates
Not DEA-scheduled — no controlled substance status

The contrast between international therapeutic approval and US research-only status is a fundamental feature of Thymosin Alpha-1 regulation. For the complete legal framework around research peptides, see our detailed guide on are peptides illegal.

FAQ

What is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino-acid synthetic peptide derived from thymus tissue. It is an immune-modulating compound studied across hepatitis, sepsis, cancer adjuvant, and immune recovery research. The compound is therapeutically approved for human use in over 35 countries internationally, though not in the United States.

Is Thymosin Alpha-1 the same as Zadaxin?

Zadaxin is the brand name under which Thymosin Alpha-1 is sold therapeutically in countries where it has approval. The molecule is the same. In the US, Thymosin Alpha-1 is sold as a research chemical under research-use-only labeling rather than as a pharmaceutical product.

Is Thymosin Alpha-1 FDA-approved?

No. Despite being approved in 35+ countries internationally for therapeutic use, Thymosin Alpha-1 has not pursued FDA approval in the United States. In the US, it is sold legally as a research chemical for in-vitro and animal research under research-use-only labeling.

How does Thymosin Alpha-1 affect the immune system?

Thymosin Alpha-1 affects multiple immune cell types: it enhances T-cell maturation, modulates dendritic cell function, engages Toll-Like Receptor signaling, promotes Th1-biased responses, and enhances NK cell activity. The combined effect supports coordinated immune function in research models, particularly relevant in immunosuppression recovery and chronic infection contexts.

What’s the half-life of Thymosin Alpha-1?

Approximately 2 hours, which is why research dosing protocols typically use multiple-times-weekly or daily administration rather than less frequent dosing. The short half-life is balanced by sustained downstream effects on immune cell populations that persist beyond the plasma clearance of the peptide itself.

Can Thymosin Alpha-1 be combined with other research peptides?

Yes — Thymosin Alpha-1 is studied in combination with other immune-active research peptides in some protocols. Its multi-pathway mechanism means it generally combines well without obvious pharmacological conflicts. Specific combination research should be informed by published methodology references.

Where can I buy research-grade Thymosin Alpha-1?

Research-grade Thymosin Alpha-1 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and N-terminal acetylation verification. Browse the OPS Peptide Science catalog for verified research-grade Thymosin Alpha-1.

Thymosin Alpha-1 stands as one of the most clinically validated peptides in the modern research catalog — with decades of international therapeutic experience supplementing its pre-clinical research base. For researchers studying immune modulation, hepatitis biology, sepsis, immune recovery, or vaccine response research, Tα1 provides a research compound with an unusually robust evidence base.

For research-grade Thymosin Alpha-1 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Peptide Education, Product Pillars, Research Protocols

SS-31: Complete Research Guide to the Mitochondrial Membrane Peptide

Posted on June 1, 2026June 1, 2026 by admin

01
Jun

Research Use Only Notice: SS-31 (Elamipretide) is a research peptide intended for in-vitro and animal research applications only. While it has been studied in clinical trials internationally, it is not FDA-approved as a drug. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

SS-31 — also known as Elamipretide — is a small synthetic peptide that targets the inner mitochondrial membrane through cardiolipin binding. Unlike most research peptides that act on cell-surface receptors, SS-31 acts at the structural level of mitochondria themselves, stabilizing membrane architecture and improving electron transport chain efficiency. This unique mechanism has made SS-31 one of the most actively studied compounds in mitochondrial dysfunction research, with applications spanning cardiac disease models, neurodegeneration research, and broader mitochondrial biology. This complete guide from the chemistry team at OPS Peptide Science walks through what SS-31 is, how the cardiolipin binding mechanism works, and how it complements MOTS-c in mitochondrial research.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is SS-31?

SS-31 is a small synthetic peptide designed to selectively accumulate in mitochondria, where it binds cardiolipin — a phospholipid unique to the inner mitochondrial membrane. The “SS” prefix refers to the Szeto-Schiller research lineage where the compound was developed. The compound has also been called Bendavia in some clinical research contexts and Elamipretide as its International Nonproprietary Name (INN).

Key facts about SS-31:

Chemical class — 4-amino-acid synthetic peptide with modified aromatic residues
Molecular weight — approximately 640 Da
Sequence — D-Arg-2′,6′-dimethyltyrosine (Dmt)-Lys-Phe-NH2
Developer — Stealth BioTherapeutics
Half-life — approximately 2 hours
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
Clinical trial status — has been studied in Phase 2 and 3 trials for cardiovascular indications; not yet FDA-approved

What distinguishes SS-31 from most research peptides is its mechanism of action. While most peptides work by binding extracellular receptors and triggering downstream signaling cascades, SS-31 crosses cell membranes, accumulates in mitochondria specifically, and acts on the inner mitochondrial membrane structure directly. This is a different mechanistic category than the receptor agonist peptides that dominate most research catalogs.

SS-31 Structure and Chemistry

The SS-31 structure was engineered specifically for mitochondrial targeting:

D-amino acid at position 1 — D-arginine prevents enzymatic degradation
Modified tyrosine (Dmt) at position 2 — 2′,6′-dimethyltyrosine provides aromatic character important for mitochondrial accumulation
Positively charged residues — the arginine and lysine carry positive charges that drive mitochondrial accumulation (mitochondria have a strong negative membrane potential)
C-terminal amide — protects against C-terminal degradation
Small size — only 4 amino acids; small enough to cross membranes through passive mechanisms

The combination of small size, positive charge, and aromatic residues makes SS-31 unusually efficient at penetrating cell membranes and concentrating in mitochondria — typically achieving 1000-fold or higher concentrations in mitochondria compared to surrounding cytoplasm.

How SS-31 Works in Research (Cardiolipin Binding Mechanism)

The SS-31 mechanism centers on cardiolipin — a phospholipid found exclusively in the inner mitochondrial membrane. Cardiolipin has several critical functions:

Stabilizes electron transport chain complexes — Complexes I, III, IV, and V all require cardiolipin for proper assembly and function
Maintains inner membrane curvature — cardiolipin’s unique structure helps form the cristae folds that increase mitochondrial surface area
Participates in apoptosis signaling — cardiolipin oxidation triggers cytochrome c release in programmed cell death
Declines with age and disease — cardiolipin levels and integrity decrease in mitochondrial dysfunction

SS-31 binds cardiolipin and produces several documented effects:

Membrane stabilization — protects cardiolipin from oxidative damage
Improved electron transport efficiency — enhances Complex I, III, and IV function in research models
Reduced ROS production — improved electron flow means less electron leakage and reactive oxygen species generation
ATP production support — better-functioning electron transport chain produces more ATP per oxygen consumed
Reduced mitochondrial swelling — protects against permeability transition pore opening

The mechanism is structural rather than signaling-based — SS-31 doesn’t activate or inhibit receptors. It supports the mechanical and chemical environment that mitochondria need to function efficiently. The published SS-31 and Elamipretide research literature on PubMed documents these mechanisms across hundreds of studies.

SS-31 Research Applications

Cardiac Research

The largest body of SS-31 research focuses on cardiac applications. Animal models of heart failure, ischemia-reperfusion injury, and cardiac dysfunction have documented SS-31 effects on cardiac function markers, ejection fraction, and survival endpoints. SS-31 has been studied in human cardiovascular clinical trials internationally — though not yet FDA-approved for cardiac indications. Current trial status is tracked on ClinicalTrials.gov.

Neurodegeneration Research

Mitochondrial dysfunction is implicated in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. SS-31 research extends into these models — measuring effects on neuronal mitochondrial function, ROS markers, and neurodegeneration progression in animal research.

Mitochondrial Disease Research

SS-31 has been studied in genetic mitochondrial disease models — Barth syndrome, Leber’s hereditary optic neuropathy, and other primary mitochondrial dysfunctions. The cardiolipin binding mechanism is particularly relevant to Barth syndrome, where cardiolipin metabolism is genetically disrupted.

Skeletal Muscle Research

Aging-related muscle dysfunction (sarcopenia) involves declining mitochondrial function. Research has documented SS-31 effects on muscle mitochondrial function, ATP production, and exercise performance markers in animal aging models.

Kidney Research

Renal ischemia-reperfusion injury, acute kidney injury, and chronic kidney disease research models have used SS-31 to study mitochondrial dysfunction contributions to kidney pathology.

Eye Research

Age-related macular degeneration and other retinal diseases involve mitochondrial dysfunction. SS-31 research extends into ophthalmologic models studying mitochondrial protection in retinal cells.

SS-31 vs MOTS-c: Mitochondrial Peptide Comparison

Both SS-31 and MOTS-c target mitochondria, but through completely different mechanisms:

Property	SS-31	MOTS-c
Size	4 amino acids	16 amino acids
Origin	Synthetic design	Mitochondrial DNA encoded
Mechanism	Structural (cardiolipin binding)	Signaling (AMPK activation)
Target	Inner mitochondrial membrane	Multiple cellular pathways
Acute effects	Mitochondrial function within hours	Gene expression over days
Primary research focus	Cardiac, neurodegeneration	Metabolic, insulin sensitivity
Clinical trial history	Yes (cardiovascular)	Limited

The two compounds are complementary rather than redundant. SS-31 provides structural mitochondrial support; MOTS-c provides metabolic and gene expression effects. Research designs studying broad mitochondrial biology sometimes use both compounds to cover different aspects of mitochondrial dysfunction.

SS-31 Dosing in Research Models

SS-31 dosing in published research varies by study design:

Subcutaneous administration — most common route in animal research
Intravenous administration — used in cardiac research and clinical trials
Daily dosing — short half-life supports once-daily protocols in most published research
Dose ranges — typically reported in mg/kg body weight in animal research; clinical trials have used various dose levels
Study duration — most pre-clinical studies run 4-12 weeks; some long-term studies extend to 6 months

Research protocols should reference published methodology for the specific model. Cardiac research uses different dosing patterns than neurodegeneration research, and animal model species affect optimal protocols significantly. For broader effect-timeline context, see our guide on how long does it take for peptides to work.

SS-31 Storage and Stability

SS-31 stability follows standard small-peptide patterns, with one notable advantage — its D-amino acid and modified tyrosine residues provide better-than-average stability:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our companion guide on how long do peptides last at room temperature.

How to Identify Quality Research-Grade SS-31

SS-31’s modified amino acids (D-arginine, dimethyltyrosine) make synthesis technically demanding. Quality criteria for research-grade SS-31:

99%+ HPLC-MS verified purity — synthesis with modified amino acids produces measurable side products requiring careful purification
Per-lot Certificate of Analysis — each batch independently tested
Mass spectrometry identity confirmation — confirms molecular weight matches SS-31 (~640 Da)
Stereochemistry verification — confirms D-amino acid configurations are correct
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every SS-31 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity and identity before opening the vial.

SS-31 Regulatory Status

Not FDA-approved — clinical trials have been conducted but no US drug approval as of this writing
Clinical trial history — Phase 2 and 3 trials in cardiovascular indications; mixed results have informed protocol refinement
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not WADA-prohibited as of current updates
Not DEA-scheduled — no controlled substance status

For the complete legal framework around research peptides like SS-31, see our detailed guide on are peptides illegal.

FAQ

What is SS-31?

SS-31 is a 4-amino-acid synthetic peptide also known as Elamipretide. It targets the inner mitochondrial membrane through cardiolipin binding, stabilizing membrane structure and improving electron transport chain function. It is one of the most actively studied compounds in mitochondrial dysfunction research.

Is SS-31 the same as Elamipretide?

Yes — SS-31 is the original research nomenclature; Elamipretide is the International Nonproprietary Name (INN) used in clinical trials and pharmaceutical contexts. The compound has also been called Bendavia in some clinical research. All three names refer to the same molecule.

How does SS-31 differ from other mitochondrial supplements?

Most mitochondrial supplements (CoQ10, PQQ, NAD+ precursors) work by providing electron transport chain cofactors. SS-31 works differently — it binds cardiolipin in the inner mitochondrial membrane, stabilizing the structural environment that the electron transport chain operates within. The mechanism is structural rather than substrate-based.

Is SS-31 FDA-approved?

No. SS-31 has been studied in Phase 2 and 3 clinical trials for cardiovascular and mitochondrial disease indications but has not received FDA approval. It is sold legally in the US as a research chemical under research-use-only labeling for in-vitro and animal research.

How long does it take SS-31 to show effects in research?

Mitochondrial function effects appear within hours in cell culture research and within days in animal research models. Tissue-level cardiac and neurological endpoints typically require 4-12 weeks of consistent dosing protocols to demonstrate measurable effects.

Can SS-31 be combined with MOTS-c in research?

Combination research is possible because the two compounds act through different mechanisms — SS-31 structurally at the mitochondrial membrane, MOTS-c through AMPK signaling and gene expression. Research designs studying broad mitochondrial biology sometimes use both compounds to cover complementary aspects. Specific combination protocols should be informed by published methodology references.

Where can I buy research-grade SS-31?

Research-grade SS-31 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and verification of D-amino acid stereochemistry. Browse the OPS Peptide Science catalog for verified research-grade SS-31.

SS-31 represents a distinct category in the research peptide catalog — a structural mitochondrial peptide rather than a receptor-targeting compound. Its cardiolipin binding mechanism enables research applications spanning cardiac dysfunction, neurodegeneration, mitochondrial disease, kidney research, and skeletal muscle biology. Combined with MOTS-c’s signaling-based mitochondrial mechanism, SS-31 forms the structural half of a complementary mitochondrial peptide research pair.

For research-grade SS-31 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: Feb 2026

Peptide Education, Product Pillars, Research Protocols

Retatrutide: Complete Research Guide to the Triple Agonist Peptide

Posted on May 24, 2026May 24, 2026 by admin

24
May

Research Use Only Notice: Retatrutide is a research peptide intended for in-vitro and animal research applications only. As of this writing, retatrutide is in late-stage clinical trials but has not received FDA approval. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

Retatrutide is a 39-amino-acid synthetic peptide that simultaneously activates three receptors — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This makes retatrutide the first triple-receptor agonist to reach late-stage clinical trials, representing the next step in the evolution of incretin-based metabolic research compounds. Where semaglutide acts on one receptor and tirzepatide on two, retatrutide engages all three — producing body composition and metabolic effects in research that exceed both predecessors. This complete guide from the chemistry team at OPS Peptide Science walks through what retatrutide is, how the triple-agonist mechanism works, and how it compares to its single- and dual-agonist predecessors.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is Retatrutide?

Retatrutide is a synthetic peptide engineered to activate three distinct receptors involved in metabolic regulation: GLP-1R, GIPR, and the glucagon receptor. The triple-receptor approach extends the metabolic research effects of single-receptor (semaglutide) and dual-receptor (tirzepatide) predecessors by adding glucagon receptor activity — which contributes to additional metabolic and energy expenditure pathways.

Key facts about retatrutide:

Chemical class — 39-amino-acid synthetic triple agonist (GLP-1 + GIP + glucagon receptor)
Molecular weight — approximately 4731 Da
Developer — Eli Lilly
Half-life — approximately 6 days (supports weekly dosing)
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
Regulatory status — in late-stage clinical trials (Phase 3); not yet FDA-approved
Research-grade form — sold under research-use-only labeling for non-human research

Retatrutide sits at the leading edge of the GLP-1 family. The compound demonstrates an interesting research pattern — each generation of incretin agonist (single → dual → triple) has produced larger metabolic effects in research, suggesting that broader receptor coverage continues to deliver additive benefits.

Retatrutide Structure and Chemistry

Retatrutide builds on the engineering principles refined in semaglutide and tirzepatide:

Glucagon-based peptide backbone — retatrutide is derived from glucagon, with modifications to give it activity at all three target receptors
Strategic amino acid substitutions — multiple substitutions tune the receptor activity balance across GLP-1R, GIPR, and glucagon receptor
Fatty acid chain attached — for albumin binding and extended half-life (similar strategy to semaglutide and tirzepatide)
Aminoisobutyric acid substitutions — protect against DPP-4 enzymatic degradation

The triple-agonist design is technically demanding because each receptor has different binding requirements. Retatrutide achieves meaningful activity at all three through careful tuning of the binding interface — though it is a “biased” agonist with characteristic activity profiles at each receptor rather than equal potency.

How Retatrutide Works in Research (Triple Agonist Mechanism)

Retatrutide’s mechanism extends the dual-receptor approach of tirzepatide by adding glucagon receptor activity. Each receptor contributes distinct effects:

GLP-1 Receptor Component

Glucose-dependent insulin secretion from pancreatic beta cells
Glucagon suppression in pancreatic alpha cells
Slowed gastric emptying
Hypothalamic appetite reduction

GIP Receptor Component

Additional insulin secretion enhancement (synergistic with GLP-1)
Direct adipose tissue effects on lipid metabolism
Centrally mediated appetite effects via brain GIP receptors

Glucagon Receptor Component (Unique to Retatrutide)

Increased energy expenditure — glucagon receptor activity raises metabolic rate
Hepatic glucose output modulation — increases glucose production in liver (counterbalanced by GLP-1’s insulin effects)
Direct fatty acid oxidation effects in liver and muscle tissue
Body composition effects from energy expenditure changes

The glucagon receptor component is what makes retatrutide unique. Adding glucagon agonism to GLP-1/GIP would seem counterproductive — glucagon normally raises blood glucose, which works against the insulin-promoting effects. But research has documented that retatrutide’s glucagon receptor activity produces useful metabolic effects (increased energy expenditure, fatty acid oxidation) without compromising the glucose-lowering effects of the GLP-1 component. The net result in research models is stronger body composition effects than either single or dual agonists deliver.

The published retatrutide research literature on PubMed documents these mechanisms in both pre-clinical and clinical-trial publications. Late-stage trials are tracked on ClinicalTrials.gov.

Retatrutide Research Applications

Metabolic Research

Research on insulin sensitivity, glucose tolerance, and broader metabolic biomarker panels. The triple-receptor mechanism produces stronger metabolic effects than dual or single agonists in head-to-head research data.

Body Composition Research

The largest research focus for retatrutide. Published research has documented body composition effects (lean mass, fat mass, distribution) that exceed both semaglutide and tirzepatide in comparable research designs. The energy expenditure mechanism from glucagon receptor activity is a key driver of this advantage.

Cardiovascular Research

Research on cardiovascular biomarkers, lipid profiles, and blood pressure trajectories. The combined receptor coverage produces broader cardiovascular research data than single-receptor approaches.

Liver Research

The glucagon receptor component makes retatrutide particularly active in liver research models. Hepatic glucose production, hepatic lipid content, and broader hepatic biology research have documented retatrutide effects beyond what GLP-1-only or dual-agonist compounds deliver.

Energy Expenditure Research

Unique to retatrutide among the GLP-1 family. Research has documented measurable increases in resting metabolic rate in animal models, attributed primarily to the glucagon receptor component. This mechanism opens research applications that single or dual agonists don’t address.

Retatrutide vs Semaglutide vs Tirzepatide

The three compounds represent successive generations of incretin agonist design. Direct comparison:

Property	Semaglutide	Tirzepatide	Retatrutide
Receptor profile	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + glucagon
Amino acids	31	39	39
Half-life	~7 days	~5 days	~6 days
FDA status	Approved	Approved	Phase 3 trials
Brand names	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound	None yet
Body composition effects in research	Strong (baseline)	Stronger	Strongest
Energy expenditure effects	Minimal	Minimal	Documented (glucagon-mediated)

For research focused on body composition endpoints, retatrutide has become the most-cited compound in head-to-head studies. For glucose-regulation research, all three compounds remain heavily used depending on the specific design. For broader metabolic and energy expenditure research, retatrutide’s triple-receptor profile provides coverage no other compound delivers.

For deeper comparison context, see our companion guides on semaglutide and tirzepatide.

Retatrutide Dosing in Research Models

Research dosing for retatrutide follows patterns established for semaglutide and tirzepatide:

Weekly subcutaneous administration — matches the 6-day half-life
Dose titration — published research typically titrates over multiple weeks because the triple-receptor mechanism produces stronger effects that benefit from gradual adaptation
Study durations 4-24 weeks — body composition and metabolic endpoints develop over multi-week protocols; some studies extend to longer durations
Dose amounts — typically reported in mg per dose in clinical trial publications; animal research uses mg/kg

Research protocols should reference published methodology for the specific research model. Because retatrutide is newer than semaglutide and tirzepatide, the available protocol literature is smaller — though growing quickly as clinical trial data publishes.

Retatrutide Storage and Stability

Retatrutide stability follows the standard GLP-1 family profile:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature.

How to Identify Quality Research-Grade Retatrutide

Retatrutide’s complexity (39 amino acids, multiple modifications, fatty acid chain) makes purity verification especially important. Quality criteria:

99%+ HPLC-MS verified purity — synthesis of complex modified peptides produces measurable degradation products; high purity is essential
Per-lot Certificate of Analysis — each batch independently tested with chromatographic profile
Mass spectrometry identity confirmation — confirms molecular weight matches retatrutide (~4731 Da), distinguishing from related compounds
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations (retatrutide is not yet FDA-approved as a drug)

At OPS Peptide Science, every retatrutide vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity and identity before opening the vial.

Retatrutide Regulatory Status

Retatrutide occupies a unique position because it is not yet FDA-approved:

Not FDA-approved — currently in Phase 3 clinical trials with Eli Lilly
No prescription pathway in the US yet — no Mounjaro/Wegovy equivalent for retatrutide
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations
WADA status — currently not specifically listed, though peptide hormones generally fall under WADA categories
Not DEA-scheduled — no controlled substance status

Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug. The only legal pathway in the US currently is the research-chemical framework under research-use-only labeling. For the complete legal framework around research peptides, see our detailed guide on are peptides illegal.

FAQ

What is retatrutide?

Retatrutide is a 39-amino-acid synthetic triple-receptor agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, retatrutide is in late-stage clinical trials but not yet FDA-approved. It exists as a research-grade compound for in-vitro and animal research under research-use-only labeling.

How does retatrutide differ from semaglutide and tirzepatide?

Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 + GIP). Retatrutide activates three (GLP-1 + GIP + glucagon). The added glucagon receptor activity contributes energy expenditure effects that the other two compounds don’t produce. Research has documented stronger body composition effects with retatrutide than either predecessor in head-to-head studies.

Is retatrutide FDA-approved?

Not yet. Retatrutide is in Phase 3 clinical trials. If trial endpoints meet expectations, FDA approval could come in coming years. Currently, retatrutide exists only as a research chemical in the US, sold under research-use-only labeling for laboratory and animal study.

Why include glucagon receptor activity if glucagon raises blood sugar?

This is the interesting design question retatrutide addresses. Glucagon receptor activity increases energy expenditure and modulates fatty acid oxidation — useful for body composition and metabolic research. The glucose-raising effect of glucagon is counterbalanced by the strong glucose-lowering effects of the GLP-1 receptor component. Net effect in research: improved body composition without compromising glucose regulation.

How long does retatrutide stay in the body?

Retatrutide has a half-life of approximately 6 days, supporting weekly dosing in research models. Full clearance from the system takes 4-5 half-lives (about 3-4 weeks) after the last dose.

Is retatrutide legal in the US?

Research-grade retatrutide is legally sold in the US under research-use-only labeling for in-vitro and animal research. It is not FDA-approved for human use. Selling retatrutide for human consumption is not legal regardless of the molecule being identical to what’s being studied in clinical trials.

Where can I buy research-grade retatrutide?

Research-grade retatrutide is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody. Browse the OPS Peptide Science catalog for verified research-grade retatrutide.

Retatrutide represents the current leading edge of incretin agonist design — the first triple-receptor agonist in late-stage clinical trials. The combination of GLP-1, GIP, and glucagon receptor activity produces metabolic and body composition research effects beyond what dual or single-receptor compounds deliver. For researchers studying metabolic regulation, body composition, energy expenditure, or comparative GLP-1 family research, retatrutide is one of the most cited next-generation peptides in the modern catalog.

For research-grade retatrutide backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Peptide Education, Product Pillars, Research Protocols

MOTS-c: Complete Research Guide to the Mitochondrial-Derived Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: MOTS-c is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that has become a focal compound in modern metabolic and longevity research. Unlike most synthetic research peptides, MOTS-c is encoded by mitochondrial DNA rather than nuclear DNA — making it one of a small group of “mitochondrial-derived peptides” (MDPs) discovered relatively recently. Research has documented MOTS-c influencing insulin sensitivity, mitochondrial biogenesis, exercise-mimetic effects, and metabolic biomarker panels in animal models. This complete guide from the chemistry team at OPS Peptide Science walks through what MOTS-c is, how the mitochondrial-origin mechanism works, and where it sits in the broader research catalog.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is MOTS-c?

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c) is a 16-amino-acid peptide encoded within the human mitochondrial 12S rRNA gene. The mitochondrial origin is biologically unusual — most peptides studied in research are encoded by nuclear DNA, while MOTS-c emerges from the small genome that mitochondria carry as a relic of their evolutionary origin as separate organisms.

Key facts about MOTS-c:

Chemical class — 16-amino-acid mitochondrial-derived peptide (MDP)
Molecular weight — approximately 2174 Da
Source — encoded by mitochondrial DNA (12S rRNA region), not nuclear DNA
Sequence — Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR)
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
Half-life — relatively short; research models use frequent dosing
Stability — stable at -20°C as lyophilized powder for 18-24 months

The mitochondrial origin makes MOTS-c part of a small but growing class of research compounds — mitochondrial-derived peptides (MDPs). Other MDPs include humanin and the SHLP (small humanin-like peptide) family. MOTS-c is the most-studied of this group due to its metabolic effects.

MOTS-c Structure and Chemistry

MOTS-c’s structure is unusual for a peptide research compound:

16 amino acids — small enough for synthetic production at high purity
Encoded by mitochondrial 12S rRNA — an unusual coding location for a functional peptide
Naturally produced — research has documented endogenous MOTS-c in human and animal tissues, particularly in muscle
Levels respond to exercise — published research has measured MOTS-c rising with exercise, supporting the “exercise-mimetic” research framing
Levels decline with age — like many bioactive peptides, MOTS-c concentrations decrease in older subjects

The age-related decline and exercise-induced increase are what make MOTS-c interesting as a research target — both findings suggest MOTS-c is part of the cellular machinery that responds to metabolic stress and aging. Studying exogenous MOTS-c administration probes whether supplementing the natural decline produces measurable effects on the same pathways.

How MOTS-c Works in Research (Mechanism)

The MOTS-c mechanism is one of the better-characterized in modern research peptide science. Documented pathways include:

AMPK activation — MOTS-c activates AMP-activated protein kinase, a central cellular energy sensor that regulates metabolism
Folate-methionine cycle modulation — research has documented effects on one-carbon metabolism, which sits upstream of multiple cellular pathways
Mitochondrial biogenesis — induces new mitochondrial formation in research models, increasing cellular mitochondrial density
Glucose homeostasis — improves insulin sensitivity and glucose disposal in animal research models
Skeletal muscle metabolism — particularly active in muscle tissue, where MOTS-c affects glucose uptake and fatty acid oxidation
Mitochondrial-nuclear signaling — MOTS-c travels from mitochondria to nucleus, where it influences gene expression

The AMPK activation mechanism positions MOTS-c alongside compounds like metformin in mechanistic research — both activate AMPK, though through different upstream signals. The mitochondrial-nuclear signaling component is particularly novel for research peptides — MOTS-c demonstrates that mitochondria don’t just produce energy; they also send signaling molecules that influence nuclear gene expression. The published MOTS-c research literature on PubMed documents these mechanisms across the past decade of investigation.

MOTS-c Research Applications

Metabolic Research

The largest body of MOTS-c research focuses on metabolic endpoints — insulin sensitivity, glucose tolerance, lipid profiles, and broader metabolic biomarker panels. Animal models studying type 2 diabetes biology, metabolic syndrome research, and obesity-related metabolic disorders have produced consistent MOTS-c data across multiple studies.

Exercise-Mimetic Research

Because endogenous MOTS-c rises with exercise, the compound has been studied as a potential “exercise mimetic” — producing some of exercise’s metabolic effects without physical activity. Research models have documented MOTS-c effects on muscle glucose uptake, mitochondrial biogenesis, and aerobic capacity markers that overlap with exercise adaptations.

Mitochondrial Biology Research

MOTS-c is one of the central research compounds in mitochondrial biology — investigating mitochondrial-nuclear communication, mitochondrial biogenesis pathways, and mitochondrial dysfunction in aging and disease models. The compound’s mitochondrial origin makes it uniquely positioned as a research probe for mitochondrial signaling.

Aging and Longevity Research

The age-related decline in endogenous MOTS-c has driven longevity research applications. Studies have measured effects on aging-related biomarkers, healthspan endpoints, and mitochondrial function across age cohorts in animal models. MOTS-c sits alongside SS-31, NAD+ precursors, and other mitochondrial compounds in the longevity research portfolio.

Bone Research

Emerging research area — MOTS-c has been documented in bone biology research models, with effects on osteoblast activity and bone density markers. This area is smaller than the metabolic research but growing.

MOTS-c Dosing in Research Models

Research dosing patterns for MOTS-c in published studies:

Subcutaneous or intraperitoneal injection — both routes appear in published animal research
Daily dosing common — short half-life supports daily administration in most protocols
Cycle-based protocols — some research designs use 4-12 week dosing cycles with washout periods
Dose amounts — typically reported in mg/kg body weight in animal research; specific protocols vary by species and endpoint
Endpoint timelines — metabolic endpoints typically measured at 4-8 weeks; longevity endpoints over longer durations

Research protocols should reference published methodology for the specific research model. The acute vs. cumulative effect timeline distinction is addressed in our guide on how long does it take for peptides to work.

MOTS-c Storage and Stability

MOTS-c stability is comparable to other small lyophilized research peptides:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature.

MOTS-c vs SS-31 and Other Mitochondrial Compounds

Several research compounds target mitochondrial biology. Brief comparison:

Compound	Type	Mechanism	Primary Research Focus
MOTS-c	Mitochondrial-derived peptide	AMPK activation, gene expression	Metabolism, insulin sensitivity, exercise mimicry
SS-31 (elamipretide)	Synthetic peptide	Cardiolipin binding, membrane stabilization	Cardiac, neurodegeneration, mitochondrial membrane
Humanin	Mitochondrial-derived peptide	Anti-apoptotic, cytoprotective	Neurodegeneration, cell survival
NAD+ precursors	Small molecule	NAD+ pool expansion	Sirtuin activation, aging biology

MOTS-c and SS-31 are the two most-cited mitochondrial peptides in modern research. They address different aspects of mitochondrial biology — MOTS-c affects gene expression and metabolic signaling, SS-31 stabilizes the inner mitochondrial membrane. Many research designs use them in parallel rather than as alternatives.

How to Identify Quality Research-Grade MOTS-c

Quality criteria for research-grade MOTS-c:

99%+ HPLC-MS verified purity — small peptide synthesis is generally manageable, but verification is essential for reproducible research
Per-lot Certificate of Analysis — each batch independently tested
Mass spectrometry identity confirmation — confirms molecular weight matches MOTS-c (~2174 Da)
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every MOTS-c vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity and identity before opening the vial.

MOTS-c Regulatory Status

MOTS-c sits in standard research-peptide regulatory territory:

Not FDA-approved — has not completed clinical trials required for human drug approval
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not WADA-prohibited — as of current updates, MOTS-c is not on the WADA Prohibited List, though this could change with future updates
Not DEA-scheduled — no controlled substance status
Newer compound — discovered around 2015, so regulatory frameworks are still adapting

For the complete legal framework around research peptides, see our detailed guide on are peptides illegal. According to NIH research literature, MOTS-c remains an active area of pre-clinical investigation, particularly in metabolic and longevity contexts.

FAQ

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA (specifically the 12S rRNA gene). It is one of a small class of “mitochondrial-derived peptides” (MDPs). Research has documented effects on insulin sensitivity, mitochondrial biogenesis, AMPK activation, and metabolic biomarker panels across animal research models.

What makes MOTS-c different from other peptides?

Two things. First, MOTS-c is encoded by mitochondrial DNA rather than nuclear DNA — unusual for a peptide. Second, MOTS-c demonstrates mitochondrial-nuclear signaling, where mitochondria send a peptide that influences nuclear gene expression. These features make MOTS-c a unique research probe for mitochondrial biology.

How does MOTS-c work?

MOTS-c activates AMP-activated protein kinase (AMPK), a central cellular energy sensor. AMPK activation produces downstream effects on glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and metabolic gene expression. MOTS-c also modulates folate-methionine cycle activity and travels from mitochondria to nucleus to influence gene expression directly.

Is MOTS-c an exercise mimetic?

Some research uses this framing because endogenous MOTS-c levels rise with exercise. Animal research has documented overlap between MOTS-c administration and exercise-induced adaptations — muscle glucose uptake, mitochondrial biogenesis, aerobic capacity markers. This doesn’t mean MOTS-c replaces exercise; it suggests both engage similar metabolic pathways.

What’s the difference between MOTS-c and SS-31?

Both target mitochondria but through different mechanisms. MOTS-c is mitochondrial-encoded and acts through AMPK and gene expression. SS-31 is a synthetic peptide that binds cardiolipin in the mitochondrial membrane, providing structural stabilization. Research often uses them as complementary tools — MOTS-c for signaling/metabolic endpoints, SS-31 for membrane and bioenergetics endpoints.

Is MOTS-c legal in the US?

Yes — MOTS-c is legally sold in the US as a research chemical for in-vitro and animal research under research-use-only labeling. It is not FDA-approved and is not currently on the WADA Prohibited List. See our detailed guide on are peptides illegal for the full framework.

Where can I buy research-grade MOTS-c?

Research-grade MOTS-c is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody. Browse the OPS Peptide Science catalog for verified research-grade MOTS-c.

MOTS-c represents a new class of research peptides — mitochondrial-derived peptides that demonstrate mitochondria-nuclear signaling. The AMPK activation mechanism, exercise-mimetic profile, and metabolic effects make MOTS-c one of the most cited compounds in modern metabolic and longevity research. For researchers studying mitochondrial biology, insulin sensitivity, or aging endpoints, MOTS-c is among the most-referenced peptides in the modern research catalog.

For research-grade MOTS-c backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Product Pillars, Peptide Education, Research Protocols

CJC-1295 + Ipamorelin: Complete Research Guide to the GH Secretagogue Stack

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: CJC-1295 and Ipamorelin are research peptides intended for in-vitro and animal research applications only. They are not FDA-approved as drugs or therapies. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

CJC-1295 and Ipamorelin together form the most-studied growth hormone secretagogue stack in modern peptide research. Each compound acts on a distinct receptor — CJC-1295 mimics growth hormone-releasing hormone (GHRH), while Ipamorelin mimics ghrelin at the GHS-R receptor — producing synergistic growth hormone release that exceeds what either compound delivers alone. This complete guide from the chemistry team at OPS Peptide Science walks through how each compound works, why researchers combine them, the DAC vs. no-DAC distinction for CJC-1295, and how the stack sits in the broader peptide research catalog.

For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Are CJC-1295 and Ipamorelin?

CJC-1295 and Ipamorelin belong to two distinct classes of growth hormone secretagogues:

CJC-1295 — a GHRH (growth hormone-releasing hormone) analog; mimics the body’s natural signal to the pituitary to release growth hormone
Ipamorelin — a GHRP (growth hormone-releasing peptide); mimics ghrelin at the GHS-R receptor and triggers growth hormone release through a separate pathway

Each compound activates a different receptor on the same target cells — pituitary somatotrophs. Combining the two simultaneously activates both pathways, producing more growth hormone release than either alone. This complementary mechanism is what makes the CJC-1295 + Ipamorelin combination the most-cited GH secretagogue stack in research literature.

CJC-1295 Structure and Mechanism

CJC-1295 is a synthetic analog of GHRH (growth hormone-releasing hormone). Key features:

30-amino-acid peptide — based on the first 29 amino acids of natural GHRH, with a 30th residue modification
Position 2 substitution — replaces alanine with D-alanine, preventing DPP-4 enzymatic degradation
Two forms exist — with DAC (long-acting) and without DAC (short-acting, also called Mod GRF 1-29)
Binds GHRH receptors on pituitary somatotrophs — same receptor as natural GHRH

The DAC (Drug Affinity Complex) modification is what differentiates the two CJC-1295 forms. With DAC, the peptide includes a maleimidopropionic acid linker that binds covalently to circulating serum albumin, extending the half-life from minutes to 6-8 days. Without DAC, CJC-1295 (Mod GRF 1-29) has a half-life of approximately 30 minutes — supporting pulsatile dosing protocols that mimic natural GHRH release patterns.

Ipamorelin Structure and Mechanism

Ipamorelin is a synthetic pentapeptide (5 amino acids) belonging to the growth hormone-releasing peptide (GHRP) class. Key features:

Pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5 amino acids with modifications for stability)
Molecular weight — approximately 712 Da
Half-life — approximately 2 hours
Binds the ghrelin receptor (GHS-R) — the same receptor activated by natural ghrelin
Highly selective — minimal effect on cortisol and prolactin compared to older GHRPs (GHRP-2, GHRP-6, hexarelin)

The selectivity of Ipamorelin is what made it stand out among GHRPs in research. Older GHRPs produce GH release but also raise cortisol and prolactin to varying degrees — which complicates research data interpretation. Ipamorelin produces measurable GH release with minimal off-target effects, making it the preferred GHRP for clean research designs.

Why Combine CJC-1295 and Ipamorelin?

Combining a GHRH analog (CJC-1295) with a GHRP (Ipamorelin) produces a synergistic effect that exceeds either compound alone. The mechanism explains why:

Two receptors, one target cell — CJC binds GHRH receptors while Ipamorelin binds GHS-R receptors, both on the same pituitary somatotrophs
Different intracellular signaling pathways — GHRH-R activates cAMP signaling; GHS-R activates phospholipase C/Ca²⁺ signaling
Convergent on GH release — both pathways end in growth hormone release, but they prime the cell through different signals
Documented synergy in research — combined administration produces 5-7x more GH release than either alone in published animal research models

The combination also restores more of the natural pulsatile GH release pattern than either compound alone — the GHRH signal “primes” the cell while the GHRP signal “triggers” release, mirroring how natural GHRH and ghrelin work together physiologically. The published CJC-1295 and Ipamorelin research literature on PubMed documents this synergy across multiple research models.

CJC-1295 + Ipamorelin Research Applications

Growth Hormone Research

The largest body of CJC-1295 + Ipamorelin research focuses on growth hormone secretion itself — measuring acute GH pulses, peak heights, and cumulative GH exposure over dosing periods. This research provides the foundation for understanding the stack’s downstream effects.

IGF-1 Trajectory Research

Growth hormone stimulates IGF-1 production primarily in the liver. Research using CJC-1295 + Ipamorelin protocols measures IGF-1 trajectories over weeks of dosing — capturing how repeated GH stimulation builds steady-state IGF-1 elevation. This is a key endpoint for studies examining downstream metabolic and tissue effects.

Body Composition Research

Animal research models studying body composition — lean mass, fat mass, distribution — use CJC-1295 + Ipamorelin protocols because elevated IGF-1 produces measurable body composition shifts over 6-12 weeks of consistent dosing.

Sleep Research

Growth hormone is closely linked to slow-wave sleep, and research on GH-stimulating peptides extends into sleep biology endpoints. CJC-1295 + Ipamorelin research has documented effects on sleep architecture in animal models.

Bone Density Research

GH and IGF-1 are central to bone metabolism. Research models studying bone density, bone turnover markers, and broader skeletal biology have documented CJC-1295 + Ipamorelin effects across multi-month protocols.

Tissue Repair Research

GH and IGF-1 support cellular repair processes. Some research models pair CJC-1295 + Ipamorelin with tissue-injury models to study repair endpoints — though specific tissue-repair compounds like BPC-157 and TB-500 remain more cited for direct repair research.

CJC-1295 With DAC vs Without DAC

The DAC distinction is one of the most important decisions in CJC-1295 research protocol design:

Property	CJC-1295 with DAC	CJC-1295 No DAC (Mod GRF 1-29)
Half-life	~6-8 days	~30 minutes
Dosing frequency	Weekly	Multiple times daily
GH release pattern	Continuous elevated	Pulsatile (mimics natural)
Receptor occupancy	Sustained	Episodic
Research use	Long-term effect studies	Pulsatile pattern research

Research design considerations:

For cumulative IGF-1 trajectory research — CJC-1295 with DAC is more practical due to weekly dosing
For pulsatile GH biology research — Mod GRF 1-29 (no DAC) more closely matches natural GHRH pulse patterns
Most combination research — uses no-DAC CJC-1295 paired with Ipamorelin in multiple-daily protocols to mimic natural GH release
Long-term metabolic studies — sometimes use DAC version for simpler weekly protocols

The choice depends on what research endpoint you’re studying. Neither form is universally “better” — they serve different research questions.

Dosing in Research Models

Combination CJC-1295 + Ipamorelin dosing patterns in published research:

Subcutaneous injection — standard route for both compounds in research models
Pre-sleep administration — common in research protocols to align with natural GH release peaks during slow-wave sleep
Multiple daily dosing — when using no-DAC CJC-1295, 2-3 doses per day to mimic pulsatile patterns
Single weekly dose — when using DAC CJC-1295, simpler protocol logistics
Cycle protocols — many research designs use 8-12 week dosing cycles with washout periods to study sustained effects
Dose amounts — typically reported in μg/kg in animal research; specific protocols vary by species and endpoint

Storage and Stability

Both compounds follow standard peptide stability profiles:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For research designs combining both peptides, OPS Peptide Science offers a pre-mixed CJC-1295 + Ipamorelin blend that simplifies the workflow — both compounds reconstituted together at standardized ratios. For protocols requiring independent dose control, separate vials of each compound are also available. See our companion guide on how long do peptides last at room temperature for detailed stability information.

How to Identify Quality CJC-1295 + Ipamorelin

Both compounds are technically demanding to synthesize cleanly. Quality criteria:

99%+ HPLC-MS verified purity for both compounds independently if sold separately, or for the blend if pre-mixed
Per-lot Certificate of Analysis documenting each compound’s purity and identity
Mass spectrometry identity confirmation — CJC-1295 (~3367 Da with DAC, ~3367 Da without DAC for Mod GRF 1-29 differs slightly), Ipamorelin (~712 Da)
Clear DAC vs no-DAC labeling — these are distinct products; mislabeling is a quality red flag
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every CJC-1295 and Ipamorelin vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity, identity, and DAC status (where applicable) before opening the vial.

Regulatory Status

CJC-1295 and Ipamorelin occupy similar regulatory positions:

Not FDA-approved — neither compound has completed clinical trials required for US drug approval
WADA-prohibited in athletic competition (peptide hormones / growth factors category)
Legal as research chemicals — sold in the US for in-vitro and animal research under research-use-only labeling
Not DEA-scheduled — no controlled substance status
Removed from compounding lists — recent FDA actions have restricted pharmacy compounding access for these compounds

For the complete legal framework around research peptides like CJC-1295 and Ipamorelin, see our detailed guide on are peptides illegal. According to NIH research literature, both compounds remain active pre-clinical research areas despite the regulatory restrictions on human use.

FAQ

What is CJC-1295?

CJC-1295 is a 30-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs and stimulates growth hormone release. Two forms exist: with DAC (6-8 day half-life) and without DAC, also called Mod GRF 1-29 (~30 minute half-life).

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide that mimics ghrelin at the GHS-R receptor, triggering growth hormone release. It is highly selective for GH release with minimal effects on cortisol and prolactin, distinguishing it from older GHRPs (GHRP-2, GHRP-6, hexarelin).

Why combine CJC-1295 and Ipamorelin?

The two compounds activate different receptors (GHRH-R and GHS-R) on the same pituitary cells. Combined administration produces synergistic growth hormone release — published research documents 5-7x more GH release than either alone in animal models. The combination also better mimics natural pulsatile GH biology.

Should I use CJC-1295 with DAC or without DAC?

Depends on the research design. With DAC supports weekly dosing for long-term IGF-1 trajectory and metabolic research. Without DAC (Mod GRF 1-29) supports multiple-daily dosing for pulsatile GH biology research. Most combination research uses no-DAC paired with Ipamorelin to mimic natural pulsatile release patterns.

Is CJC-1295 + Ipamorelin legal in the US?

Yes — both compounds are legally sold as research chemicals for in-vitro and animal research under research-use-only labeling. Neither is FDA-approved for human use, and WADA prohibits both in athletic competition. See our detailed guide on are peptides illegal for the full framework.

How long does it take to see effects from CJC-1295 + Ipamorelin in research?

Acute GH release peaks within 30-90 minutes of administration in research models. Cumulative IGF-1 elevation builds over 2-4 weeks of consistent dosing. Body composition and metabolic endpoints typically require 6-12 weeks. Specific timelines depend on the research endpoint being measured.

Where can I buy research-grade CJC-1295 + Ipamorelin?

Research-grade CJC-1295 and Ipamorelin are sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity for each compound, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and clear DAC vs no-DAC labeling. Browse the OPS Peptide Science catalog for verified research-grade CJC-1295 and Ipamorelin, including pre-mixed blends.

The CJC-1295 + Ipamorelin combination remains the gold-standard growth hormone secretagogue stack in modern peptide research. The dual-receptor mechanism produces synergistic GH release that exceeds either compound alone, supporting research across growth hormone biology, IGF-1 trajectories, body composition, sleep biology, and bone density endpoints. For researchers studying the GH axis at any level, this stack is one of the most-cited combinations in the modern catalog.

For research-grade CJC-1295 and Ipamorelin backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Uncategorized, Peptide Education, Product Pillars, Research Protocols

GHK-Cu: Complete Research Guide to the Copper Tripeptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: GHK-Cu is a research peptide intended for in-vitro and animal research applications. Cosmetic-grade GHK-Cu formulations exist as permitted cosmetic ingredients and are distinct from research-grade compound. Nothing in this article constitutes medical advice, dermatologic guidance, or instructions for personal use.

GHK-Cu — glycyl-L-histidyl-L-lysine bound to a copper ion — is one of the most extensively studied copper peptides in dermal biology research. The compound occurs naturally in human plasma at concentrations that decline progressively with age, a feature that has driven decades of research interest. Published literature documents GHK-Cu modulating over 4,000 genes related to repair, regeneration, and aging biology — making it one of the most mechanistically diverse research peptides in the modern catalog. This complete guide from the chemistry team at OPS Peptide Science walks through what GHK-Cu is, how it works, and where it sits across skin biology, wound healing, and gene expression research.

For the broader skin biology research context, see our companion guides on what do copper peptides do for your skin, can you use peptides with retinol, and peptides for anti-aging and longevity.

What Is GHK-Cu?

GHK-Cu is a copper-binding tripeptide consisting of three amino acids — glycine, L-histidine, and L-lysine — coordinated with a copper(II) ion. The peptide occurs naturally in human plasma at high concentrations in young adults (~200 ng/mL), declining substantially by age 60 (~80 ng/mL). This natural decline drives much of the research interest in supplementing exogenous GHK-Cu.

Key facts about GHK-Cu:

Chemical class — copper-coordinated tripeptide (3 amino acids)
Molecular weight — approximately 401 Da (340 Da for the peptide + ~62 Da for the copper coordination)
Sequence — Gly-His-Lys (glycyl-L-histidyl-L-lysine)
Form — typically supplied as lyophilized blue-colored powder (color comes from the copper coordination); reconstituted with bacteriostatic water
Cosmetic-grade exists — GHK-Cu is permitted as a cosmetic ingredient in skincare products at controlled concentrations
Research-grade exists — sold under research-use-only labeling for in-vitro and animal research, typically 99%+ purity

The blue color of properly reconstituted GHK-Cu is a quick visual indicator of the copper coordination — uncomplexed GHK has no significant color. If a GHK-Cu solution appears clear or colorless, the copper coordination may be incomplete or the compound may be primarily uncomplexed GHK rather than GHK-Cu.

GHK-Cu Structure and Chemistry

The GHK-Cu structure is small but chemically elegant. Key features:

Copper coordination at the histidine imidazole — the histidine ring nitrogen is the primary copper-binding site
Additional copper coordination via amine groups — the lysine side chain and N-terminal amine participate in the copper binding pocket
Square-planar copper geometry — the copper(II) ion sits in a defined geometric configuration that determines activity
Naturally occurring — same molecular structure as the GHK-Cu found in human plasma, just synthesized for research-grade purity

The copper coordination is what gives GHK-Cu most of its activity — research has documented different activity profiles for GHK alone versus GHK-Cu. The copper ion isn’t an accessory; it’s central to the compound’s mechanism.

How GHK-Cu Works in Research (Mechanism)

Unlike most research peptides that act through a single receptor, GHK-Cu has been documented to modulate multiple biological pathways simultaneously. This is one of the unusual features that drives research interest. Documented mechanisms include:

Gene expression modulation — published research has measured GHK-Cu influence on the expression of over 4,000 genes related to repair, regeneration, antioxidant systems, and cellular aging
Copper-dependent enzyme cofactor activity — copper is required for several antioxidant enzymes (most notably superoxide dismutase), and GHK-Cu participates in copper delivery to these systems
Collagen synthesis upregulation — fibroblast cultures exposed to GHK-Cu produce measurably more Type I collagen than control conditions
Glycosaminoglycan synthesis — hyaluronic acid and related GAGs increase in research models
Fibroblast proliferation and migration — measured in cell culture studies
Anti-inflammatory effects — pro-inflammatory cytokine modulation in research models
DNA repair pathway engagement — research has documented effects on genes involved in cellular DNA repair

The multi-pathway, multi-target nature of GHK-Cu’s mechanism is what makes the compound interesting in research contexts — it doesn’t fit the “one receptor, one effect” model of most synthetic peptides. The published GHK-Cu research literature on PubMed documents these mechanisms across hundreds of studies.

GHK-Cu Research Applications

GHK-Cu research applications span several research areas, all building on the mechanism diversity:

Skin Biology Research

The largest body of GHK-Cu research focuses on skin biology endpoints — collagen synthesis, fibroblast activity, dermal extracellular matrix biology, and broader skin aging research. The research literature spans cell culture studies, animal dermal models, and topical formulation research.

Wound Healing Research

Animal wound healing models — burn, surgical, diabetic ulcer — have documented GHK-Cu effects on re-epithelialization, granulation tissue formation, and overall wound closure timelines. The mechanism involves multiple pathways: angiogenesis, fibroblast migration, anti-inflammatory effects, and collagen production.

Hair Follicle Research

Research on hair follicle stem cells, follicle cycling, and broader hair biology has documented GHK-Cu effects. Some published research links GHK-Cu to hair density and growth phase markers in animal models.

Antioxidant System Research

Copper is a cofactor for several antioxidant enzymes (Cu/Zn superoxide dismutase being the most studied). GHK-Cu’s role in copper delivery makes it relevant to antioxidant system research — published studies document effects on cellular oxidative stress markers.

Aging Biology Research

GHK-Cu’s natural decline with age and its broad gene expression effects have driven aging-biology research. Research models studying senescence markers, DNA repair pathways, and cellular aging endpoints have documented GHK-Cu effects across multiple study designs.

Cosmetic-Grade vs Research-Grade GHK-Cu

GHK-Cu is unusual among research peptides because it exists in two distinct legal categories in the United States:

Category	Cosmetic-Grade	Research-Grade
Form	Finished cosmetic product	Lyophilized research vial
Sold as	Skincare serum, cream	Research peptide
Intended for	Topical cosmetic use	In-vitro and animal research
Regulation	FDA cosmetic regulations	Research-use-only labeling
Concentration	Controlled (typically 0.5-2% in formulation)	Pure compound for research dosing
Purity standards	Cosmetic-grade (variable)	99%+ HPLC-MS verified

The two categories serve different purposes and are not interchangeable. Cosmetic-grade GHK-Cu is designed for topical use within finished products. Research-grade GHK-Cu is a reagent for laboratory studies, sold under research-use-only labeling and never for human consumption.

GHK-Cu Dosing in Research Models

Research dosing of GHK-Cu varies significantly by application area:

Topical research formulations — typically reported in % w/w of finished formulation (0.05-2%); applied to dermal research sites
Cell culture concentrations — typically reported in nM to μM ranges; depends on cell type and endpoint
Animal model injection studies — subcutaneous administration typical; dosing reported in mg/kg body weight
Daily dosing common — GHK-Cu has a relatively short half-life requiring frequent administration in research protocols

Research protocols should always reference published methodology for the specific research model. Topical and injection routes produce different research data and aren’t directly comparable.

GHK-Cu Storage and Stability

GHK-Cu stability requires more attention than most research peptides because of the copper coordination. The copper-peptide complex can be destabilized by:

Strong reducing agents — can strip the copper from the complex
Chelating agents — can sequester the copper away from the peptide
Extreme pH conditions — can disrupt the coordination geometry
Heat and light exposure — standard peptide degradation factors

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature. Protect GHK-Cu from light during storage when possible — opaque containers or refrigerator cardboard boxes work well.

GHK-Cu vs AHK-Cu and Other Copper Peptides

Several related copper peptides exist in research contexts. Brief comparison:

Compound	Sequence	Main Research Focus
GHK-Cu	Gly-His-Lys + Cu	Most studied; broad research applications
AHK-Cu	Ala-His-Lys + Cu	Hair research; complementary to GHK-Cu
GHK (uncomplexed)	Gly-His-Lys (no copper)	Limited research; different activity profile
Custom copper peptides	Various	Emerging research area

GHK-Cu remains the most-cited research compound in this family due to its substantial published literature and well-characterized mechanism. Other copper peptides extend the research into specific applications (AHK-Cu in hair biology, custom variants for receptor-specific research).

How to Identify Quality Research-Grade GHK-Cu

Research-grade GHK-Cu quality criteria differ slightly from other peptides because of the copper coordination:

Blue-colored lyophilized powder — confirms the copper is coordinated with the peptide; a white powder may indicate uncomplexed GHK
99%+ HPLC-MS verified purity — confirms the compound is GHK-Cu, not degradation products
Per-lot Certificate of Analysis — each batch independently tested
Mass spectrometry identity confirmation — confirms molecular weight matches GHK-Cu (~401 Da)
Copper content verification — confirms the copper coordination is present, not just GHK peptide alone
Research-use-only labeling — required for the non-cosmetic, non-pharmaceutical category

At OPS Peptide Science, every GHK-Cu vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming HPLC-MS purity and identity verification before opening the vial.

GHK-Cu Regulatory Status

GHK-Cu occupies a unique dual-category position in US regulation:

Cosmetic-grade GHK-Cu — permitted as a cosmetic ingredient in skincare products at controlled concentrations
Research-grade GHK-Cu — sold under research-use-only labeling for in-vitro and animal research
Not FDA-approved as a drug — no pharmaceutical approval for systemic therapeutic use
Not WADA-prohibited — unlike some peptides, GHK-Cu is not on the WADA Prohibited List as of current updates
Not DEA-scheduled — no controlled substance status

For the complete legal framework around research peptides, see our detailed guide on are peptides illegal. According to NIH dermal research literature, GHK-Cu remains an active area of investigation across multiple research applications.

FAQ

What is GHK-Cu?

GHK-Cu is a tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper ion. It occurs naturally in human plasma at concentrations that decline with age and has been extensively studied in skin biology, wound healing, antioxidant, and gene expression research.

What’s the difference between GHK and GHK-Cu?

GHK is the uncomplexed tripeptide. GHK-Cu is the same peptide bound to a copper ion. Research has documented different activity profiles between the two — the copper coordination is functionally important, and most of the documented skin biology and wound healing effects are attributed to the copper-bound form.

How does GHK-Cu affect collagen?

Research has documented GHK-Cu upregulating Type I collagen synthesis in fibroblast cultures. The mechanism involves both direct effects on fibroblast activity and modulation of genes involved in extracellular matrix protein synthesis (decorin, glycosaminoglycans, etc.).

Can GHK-Cu be used with retinol?

Combination research exists but requires careful design — pH and stability interactions can compromise both compounds in direct mixing. Sequenced application (separate products at different times) is the more common research approach. See our detailed guide on can you use peptides with retinol for the complete picture.

Is GHK-Cu legal to buy in the US?

Yes — cosmetic-grade GHK-Cu is permitted as a skincare ingredient. Research-grade GHK-Cu is sold under research-use-only labeling for in-vitro and animal research. Neither is sold or prescribed for human therapeutic consumption.

How is GHK-Cu stored?

Lyophilized GHK-Cu powder stores at -20°C for 18-24 months. Reconstituted GHK-Cu in bacteriostatic water stores at 2-8°C for 21-28 days. Protect from light during storage. See our complete guide on peptide refrigeration requirements.

Where can I buy research-grade GHK-Cu?

Research-grade GHK-Cu is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include blue-colored lyophilized powder (confirming copper coordination), 99%+ HPLC-MS verified purity, and per-lot Certificates of Analysis. Browse the OPS Peptide Science catalog for verified research-grade GHK-Cu.

GHK-Cu stands out among research peptides for its multi-pathway mechanism, its natural occurrence in human biology, and its broad applicability across skin biology, wound healing, and aging research. For researchers studying collagen synthesis, dermal biology, gene expression, or antioxidant pathways, GHK-Cu remains one of the most-cited copper peptides in the modern research catalog.

For research-grade GHK-Cu backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Product Pillars, Peptide Education, Research Protocols

Semaglutide: Complete Research Guide to GLP-1 Receptor Agonist Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: The semaglutide discussed in this article as a research compound is intended for in-vitro and animal research applications only. FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) require a prescription from a licensed physician and are distinct from research-grade semaglutide. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

Semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide that has become one of the most-studied compounds in modern metabolic research. Originally developed for type 2 diabetes management, semaglutide is now FDA-approved across three commercial products — Ozempic, Wegovy, and Rybelsus — and exists as a separate research compound for in-vitro and animal study. This complete guide from the chemistry team at OPS Peptide Science walks through what semaglutide is, how it works mechanistically, where it sits in metabolic research, and how the FDA-approved forms differ from the research-grade compound.

For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is Semaglutide?

Semaglutide is a synthetic peptide designed to mimic and extend the action of glucagon-like peptide-1 (GLP-1) — a naturally occurring incretin hormone that regulates blood glucose, insulin secretion, and appetite. Native GLP-1 has a very short half-life (1-2 minutes) due to rapid enzymatic degradation. Semaglutide was engineered to resist this degradation, extending the biological half-life to approximately 7 days.

Key facts about semaglutide:

Chemical class — 31-amino-acid GLP-1 analog with chemical modifications for stability
Molecular weight — approximately 4114 Da
Half-life — approximately 7 days (intentionally engineered to be long-acting)
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
FDA-approved products — Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D)
Research-grade form — same compound, sold under research-use-only labeling for non-human research

Semaglutide is unusual among research peptides in that it has fully completed FDA approval for human therapeutic use. The research-grade version sold by OPS Peptide Science is the same molecule, supplied for laboratory and animal research applications under research-use-only labeling rather than as a prescription pharmaceutical.

Semaglutide Structure and Chemistry

Semaglutide’s design reflects two decades of GLP-1 analog research. Key structural features:

Based on native GLP-1 sequence — 94% similarity to human GLP-1, with critical modifications
Amino acid substitution at position 8 — alanine replaced with aminoisobutyric acid (Aib), preventing DPP-4 enzyme degradation
Fatty acid chain attached — a C18 fatty acid linked via a spacer enables albumin binding, extending the half-life from minutes to days
Substitution at position 34 — lysine replaced with arginine, supporting the fatty acid modification

These three modifications — Aib substitution, fatty acid chain, and lysine substitution — are what transform native GLP-1 (clinically impractical due to 2-minute half-life) into semaglutide (suitable for weekly dosing). The chemistry is elegant and well-documented in the published literature.

How Semaglutide Works in Research (Mechanism)

Semaglutide is a GLP-1 receptor agonist — it binds and activates the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed on pancreatic beta cells, brain cells, and several other tissues. The mechanism cascades:

Pancreatic beta cells — GLP-1R activation stimulates glucose-dependent insulin secretion, increasing insulin in response to elevated blood glucose
Alpha cells (glucagon) — GLP-1R activation suppresses glucagon secretion in hyperglycemic conditions
Gastric emptying — semaglutide slows gastric emptying, reducing post-meal blood glucose spikes
Hypothalamic satiety centers — GLP-1R expression in the brain mediates appetite reduction and increased satiety
Cardiovascular tissue effects — documented in cardiac research, with measurable effects on cardiovascular biomarkers

The combination of pancreatic glucose regulation and hypothalamic appetite reduction explains semaglutide’s dual research applications — metabolic regulation and body composition endpoints. The published semaglutide and GLP-1 research literature on PubMed documents these mechanisms across thousands of studies.

Semaglutide Research Applications

Semaglutide research spans several major application areas:

Metabolic Research

The largest body of semaglutide research focuses on metabolic endpoints — insulin sensitivity, glucose tolerance, HbA1c trajectories, and broader metabolic biomarker panels. Animal models studying glucose homeostasis and insulin resistance produce reproducible data with semaglutide protocols.

Body Composition Research

Research on adipose tissue, body composition trajectories, and weight management endpoints in animal models. The hypothalamic appetite mechanism translates to measurable food intake reduction and body composition changes in research subjects over multi-week protocols.

Cardiovascular Research

GLP-1 receptors are expressed in cardiovascular tissues, and research has documented semaglutide effects on cardiovascular biomarkers, inflammatory markers, and lipid profiles in animal research models. This area has generated substantial clinical-trial literature for the FDA-approved forms.

Neurological Research

Emerging research area — GLP-1R expression in brain tissue has driven research on semaglutide effects in neurodegeneration models, cognitive endpoints, and addiction biology. The findings are early-stage but the research literature is growing rapidly.

Inflammatory Research

Anti-inflammatory effects independent of glucose regulation have been documented in research models. Some research links semaglutide to reduced inflammatory markers in metabolic syndrome-related research.

FDA-Approved Semaglutide vs. Research-Grade Semaglutide

This is the most important distinction for understanding semaglutide in the market. Two parallel categories exist:

Category	FDA-Approved	Research-Grade
Sold as	Ozempic, Wegovy, Rybelsus	Research peptide vial
Source	Pharmaceutical manufacturer (Novo Nordisk)	Research peptide supplier
Prescription required	Yes	No (research-use-only labeling)
Intended for	Human therapeutic use	In-vitro and animal research
Approved indications	T2D, obesity, T2D/CVD risk	None (not a drug)
Compound molecule	Semaglutide	Semaglutide

Critical distinction: the molecule is the same, but the regulatory category is different. FDA-approved semaglutide is sold as a pharmaceutical product with full chain-of-custody, prescription oversight, and regulated manufacturing under cGMP. Research-grade semaglutide is sold for laboratory study under research-use-only labeling — never for human consumption. Selling research-grade semaglutide for human use is illegal regardless of the molecule being identical.

For the complete legal framework, see our detailed guide on are peptides illegal and our overview on who can prescribe peptides.

Semaglutide Dosing in Research Models

Research dosing of semaglutide varies by study design but follows a few common patterns:

Weekly subcutaneous administration — matches the 7-day half-life, allowing steady-state plasma levels in research models
Dose titration — published research typically starts at lower doses and titrates upward to study tolerance and effect curves
4-12 week study duration — most metabolic endpoints require several weeks to demonstrate measurable effects
Animal model dosing — typically reported in μg/kg body weight in published research; specific protocols vary by species and endpoint

The long half-life is what makes semaglutide research practical — weekly dosing is convenient for animal protocols and maintains stable plasma concentrations across the research duration. The acute onset versus cumulative timeline question is addressed in our guide on how long does it take for peptides to work.

Semaglutide Storage and Stability

Semaglutide stability profile is similar to other lyophilized research peptides:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature.

Semaglutide vs Tirzepatide vs Liraglutide

The GLP-1 receptor agonist family includes several research peptides. Brief comparison:

Peptide	Receptor Profile	Half-life	FDA-Approved Brand(s)
Semaglutide	GLP-1 receptor only	~7 days	Ozempic, Wegovy, Rybelsus
Tirzepatide	GLP-1 + GIP dual agonist	~5 days	Mounjaro, Zepbound
Liraglutide	GLP-1 receptor only	~13 hours	Saxenda, Victoza
Retatrutide	GLP-1 + GIP + glucagon receptor triple agonist	~6 days	Not yet FDA-approved (clinical trials)

Research designs comparing these compounds explore the GLP-1-only mechanism (semaglutide) versus dual-receptor (tirzepatide) versus triple-receptor (retatrutide) effects on metabolic endpoints. Each compound has different research applications based on its receptor profile.

How to Identify Quality Research-Grade Semaglutide

Because semaglutide is a high-demand research compound, the supplier market includes variable quality. Quality criteria:

99%+ HPLC-MS verified purity — large peptide synthesis (31 amino acids with modifications) is technically demanding; purity verification is essential
Per-lot Certificate of Analysis — each batch independently tested with full chromatographic profile
Mass spectrometry identity confirmation — confirms the modified molecule matches semaglutide (4114 Da), distinguishing from native GLP-1 fragments or degradation products
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations for the non-pharmaceutical product

At OPS Peptide Science, every semaglutide vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity, identity, and chain of custody before opening the vial.

Semaglutide Regulatory Status

Semaglutide regulatory status is unique among research peptides because it has parallel pharmaceutical approval:

FDA-approved for human therapeutic use — three commercial products (Ozempic, Wegovy, Rybelsus) cleared for type 2 diabetes and obesity indications
Sold as prescription drug through licensed pharmacies
Research-grade form sold under research-use-only labeling — same molecule, different regulatory category, not for human consumption
WADA-prohibited in athletic competition (peptide hormones category)
Not DEA-scheduled — no controlled substance status

The FDA’s Drugs@FDA database lists the approved semaglutide products and their indications. For research use of the molecule, the research-use-only framework applies.

FAQ

What is semaglutide?

Semaglutide is a 31-amino-acid synthetic peptide that acts as a GLP-1 receptor agonist. It is FDA-approved as Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral type 2 diabetes). It also exists as a research-grade compound sold under research-use-only labeling for in-vitro and animal research.

Is research-grade semaglutide the same as Ozempic?

The molecule is the same — both are semaglutide. The regulatory categories are different. Ozempic is the FDA-approved pharmaceutical product sold by prescription. Research-grade semaglutide is the same molecule sold for laboratory and animal research under research-use-only labeling, not for human consumption.

How long does semaglutide stay in the body?

Semaglutide has an unusually long half-life of approximately 7 days, engineered through chemical modifications that resist enzymatic degradation. This supports weekly dosing in research models. Full clearance from the system takes 4-5 half-lives (about 4-5 weeks) after the last dose.

How does semaglutide work?

Semaglutide binds and activates the GLP-1 receptor (GLP-1R) on pancreatic beta cells, hypothalamic appetite centers, and other tissues. This produces glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and reduced appetite. The combined mechanism produces the metabolic effects documented in research.

What’s the difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1 receptor agonist only. Tirzepatide is a dual GLP-1 and GIP receptor agonist — activating both incretin receptors simultaneously. Research compares the single-receptor versus dual-receptor approaches, with tirzepatide showing additional effects beyond what GLP-1 activation alone produces in metabolic research models.

How is semaglutide stored in research?

Lyophilized semaglutide powder stores at -20°C for 18-24 months. Reconstituted semaglutide in bacteriostatic water stores at 2-8°C for 21-28 days. Standard peptide storage protocols apply — see our guide on peptide refrigeration requirements.

Where can I buy research-grade semaglutide?

Research-grade semaglutide is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody documentation. Browse the OPS Peptide Science catalog for verified research-grade semaglutide.

Semaglutide stands at the intersection of two regulatory worlds — an FDA-approved pharmaceutical (Ozempic, Wegovy, Rybelsus) and a research-grade compound for laboratory study. The molecule is the same; the contexts and labeling differ. For metabolic, body composition, cardiovascular, and increasingly neurological research, semaglutide remains one of the most-cited research peptides in the modern catalog.

For research-grade semaglutide backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Product Pillars, Peptide Education, Research Protocols

TB-500: Complete Research Guide to Thymosin Beta-4 Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: TB-500 is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

TB-500 is the synthetic peptide version of thymosin beta-4 — a naturally occurring 43-amino-acid peptide found throughout human and animal tissues. Research on TB-500 spans cardiac repair, dermal wound healing, corneal injury, and broader cell migration biology. The compound has been a focal point of tissue-repair research for decades, with substantial published literature documenting its actin-binding mechanism and downstream effects. This complete guide from the chemistry team at OPS Peptide Science walks through what TB-500 is, how it works in research models, where it sits in the broader research catalog, and how it pairs with BPC-157 in combination protocols.

For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is TB-500?

TB-500 is the synthetic, research-grade version of thymosin beta-4 (TB-4) — a 43-amino-acid peptide naturally produced in nearly all human and animal tissues. The “500” designation refers to the research nomenclature, not a fragment number — TB-500 is the full-length thymosin beta-4 sequence, synthesized for laboratory use.

Key facts about TB-500:

Chemical class — 43-amino-acid peptide, synthetic version of naturally occurring thymosin beta-4
Molecular weight — approximately 4963 Da
Source — synthesized to match the natural human thymosin beta-4 sequence
Form — typically supplied as lyophilized (freeze-dried) powder; reconstituted with bacteriostatic water for research administration
Half-life — longer than most small peptides due to tissue binding; effective biological half-life is measured in days rather than hours
Stability — stable at -20°C as lyophilized powder for 18-24 months; reconstituted solutions stable for 21-28 days refrigerated

Unlike many research peptides, TB-500’s natural counterpart (thymosin beta-4) is one of the most abundant peptides in mammalian cells, present at high concentrations in platelets, tissues, and circulating plasma. This means TB-500 research has a robust foundation in the natural biology of the compound — researchers know what the molecule does because cells use it for actin regulation and repair as a normal function.

TB-500 Structure and Chemistry

The TB-500 / thymosin beta-4 sequence is one of the most characterized small peptides in cell biology research. Key structural features:

43 amino acids — longer than most synthetic research peptides, which sit in the 5-15 amino acid range
Actin-binding domain — the central functional region that gives the peptide its primary biological activity
N-terminal acetylation — naturally occurring in human thymosin beta-4; synthetic TB-500 typically reproduces this modification for stability
Highly conserved across species — the thymosin beta-4 sequence is nearly identical across mammals, supporting cross-species research translation

The actin-binding domain is what makes TB-500 functionally interesting — it’s not a hormone analog targeting a single receptor, but a cytoskeletal modulator influencing cell shape, migration, and tissue organization at the structural level.

How TB-500 Works in Research (Mechanism)

The TB-500 mechanism is among the better-characterized of research peptides. Documented activities:

G-actin sequestration — TB-500 binds free G-actin monomers, regulating the dynamic balance between G-actin and F-actin (filamentous actin)
Actin polymerization control — by controlling G-actin availability, TB-500 influences when and where actin filaments form, which determines cell shape and movement
Cell migration regulation — fundamental to tissue repair, where cells must migrate to injury sites
Anti-inflammatory effects — independent of actin binding, TB-500 has been documented to modulate inflammatory pathways
Angiogenesis support — research has measured effects on endothelial cell migration and new blood vessel formation
Stem cell activation — published research documents effects on progenitor cell activity in repair contexts

The actin biology mechanism is what gives TB-500 its broad research applications. Almost any tissue repair process involves cell migration, and cell migration requires actin reorganization — which TB-500 directly influences. The thymosin beta-4 tissue repair literature on PubMed documents the mechanism across hundreds of studies.

TB-500 Research Applications

The research literature on TB-500 covers several major application areas:

Cardiac Research

One of the most extensively studied TB-500 applications is in cardiac injury research. Animal models of myocardial infarction have documented measurable effects on cardiac tissue repair, reduced scar tissue formation, and improved heart function endpoints in TB-500-treated subjects. This research extended to clinical trials in some countries (though TB-500 remains non-FDA-approved in the US).

Dermal Wound Healing Research

Skin injury models — burn, surgical wound, diabetic ulcer — show accelerated re-epithelialization, improved granulation tissue quality, and reduced scarring in TB-500-treated research subjects. The compound’s effects on cell migration directly support the wound-healing process at the cellular level.

Corneal Research

Ocular research includes corneal wound healing models, dry eye research, and corneal epithelial regeneration studies. TB-500 has documented effects on corneal repair markers across multiple animal research models.

Musculoskeletal Research

Tendon, ligament, and muscle injury research uses TB-500 to study cell migration during repair. The published research overlaps with BPC-157 research in this area, though the mechanisms are distinct — BPC-157 works through VEGF and angiogenesis, TB-500 works through actin and cell migration.

Hair Follicle Research

A smaller but documented research area on TB-500 effects on hair follicle stem cells and follicle activity. Animal models have measured changes in follicle cycling and stem cell markers.

TB-500 Dosing in Research Models

TB-500 dosing in published research models has distinct features compared to shorter peptides:

Less frequent dosing — TB-500’s effective biological half-life supports less frequent administration than short-half-life peptides; twice-weekly or weekly protocols appear in published research
Larger absolute dose ranges — because the peptide is larger (43 aa vs. 15 aa for BPC-157), research doses tend to be larger in mg amounts
Subcutaneous or intramuscular — both routes documented in published research; SC is more common
Tissue depot effects — TB-500 binds tissues and produces effects beyond what acute plasma levels would predict, complicating simple pharmacokinetic interpretations

Research protocols should reference published methodology for the specific research model. Tissue-binding behavior means TB-500 dosing protocols require careful design — single doses can produce extended effects, while frequent dosing may not produce proportional additive responses.

TB-500 Storage and Stability

TB-500 stability profile aligns with most lyophilized research peptides:

Storage Condition	Form	Stability Window
-80°C (ultra-low freezer)	Lyophilized powder	3-5+ years
-20°C (standard lab freezer)	Lyophilized powder	18-24 months
2-8°C (refrigerated)	Lyophilized powder	6-12 months
Room temperature	Lyophilized powder	2-4 weeks for transit
2-8°C (refrigerated)	Reconstituted in BAC water	21-28 days

For practical storage protocols, see our companion guide on how long do peptides last at room temperature. Larger peptides like TB-500 (vs. smaller compounds like BPC-157) sometimes show slightly different oxidation susceptibility — protocols that work for both compounds generally cover TB-500 safely.

TB-500 + BPC-157 Combination Research (Wolverine Stack)

One of the most-discussed research applications is the combination of TB-500 with BPC-157 — popularly called the Wolverine Stack in research and biohacking discussions. The rationale:

Different mechanisms — TB-500 acts on actin and cell migration; BPC-157 acts on VEGF, angiogenesis, and multiple signaling pathways
Different half-lives — TB-500’s tissue-binding gives extended effects; BPC-157’s shorter half-life allows acute signaling
Potentially complementary — TB-500 supports the cell migration phase of repair; BPC-157 supports the angiogenesis and inflammation modulation phases
Documented in published research — both compounds appear in combination protocols across animal tissue-repair studies

Research design for combination studies requires separate reconstitution, alternating injection sites, and careful documentation of each compound’s contribution to the endpoint. The Wolverine Stack name is informal — published research literature uses BPC-157 + TB-500 terminology — but the combination protocol is real and documented. See our overview on peptides for healing and recovery for the broader context.

How to Identify Quality TB-500

TB-500’s larger size (43 amino acids vs. 15 for BPC-157) makes it more challenging to synthesize cleanly. Quality criteria for research-grade TB-500:

99%+ purity confirmed by HPLC-MS analysis — synthesis of longer peptides produces more degradation products; purity verification is especially important
Per-lot Certificate of Analysis — each batch independently tested with full chromatographic profile
Mass spectrometry identity confirmation — confirms the molecular weight matches TB-500 (4963 Da), distinguishing from shorter degradation products
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial, no discoloration or moisture damage
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every TB-500 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming the full HPLC-MS purity report and identity verification before opening the vial.

TB-500 Regulatory Status

TB-500 / thymosin beta-4 occupies a specific position in US regulatory frameworks:

Not FDA-approved — has not completed clinical trials required for human drug approval in the US
WADA-prohibited — listed under category S2 (peptide hormones, growth factors, related substances), banned in and out of athletic competition
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not DEA-scheduled — no controlled substance status
Some clinical research history — has been studied in clinical trials internationally for cardiac and dermal indications, though not FDA-approved

For the complete legal framework around research peptides like TB-500, see our detailed guide on are peptides illegal. According to NIH research literature, TB-500 remains an active pre-clinical research compound across multiple tissue-repair applications.

FAQ

What is TB-500?

TB-500 is the synthetic, research-grade version of thymosin beta-4 — a 43-amino-acid peptide naturally produced in nearly all human and animal tissues. It is one of the most-studied tissue-repair research peptides, with substantial published literature documenting effects on cardiac, dermal, corneal, and musculoskeletal injury models.

Is TB-500 the same as thymosin beta-4?

Yes — TB-500 is the synthetic research-grade version of thymosin beta-4. The two names refer to the same compound, with “TB-500” being the research nomenclature and “thymosin beta-4” being the biological name. Some sources also use “TB4” as a shorthand.

Is TB-500 legal in the US?

TB-500 is legally sold in the US as a research chemical for in-vitro and animal research, under research-use-only labeling. It is not FDA-approved for human use. WADA has prohibited it in athletic competition.

How long does TB-500 stay in the body in research?

TB-500’s plasma half-life is short, but its biological half-life is much longer due to tissue binding. Effective effects in research models can extend for several days after a single dose — longer than the plasma half-life would suggest. This is why TB-500 research protocols often use less frequent dosing (twice-weekly or weekly) than shorter peptides.

What’s the difference between BPC-157 and TB-500?

Both are tissue-repair research peptides, but they act through different mechanisms. BPC-157 (15 amino acids) acts on VEGF, angiogenesis, and multiple signaling pathways. TB-500 (43 amino acids) acts on actin sequestration and cell migration. They are often combined in research protocols (the Wolverine Stack) because the mechanisms complement rather than overlap.

How is TB-500 administered in research?

Most published TB-500 research uses subcutaneous injection. Intramuscular injection also appears in some research protocols. Less frequent dosing schedules (twice-weekly or weekly) are common due to TB-500’s tissue-binding properties and extended biological half-life. See our complete guide on how are peptides administered for context across administration routes.

Where can I buy research-grade TB-500?

Research-grade TB-500 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody. Browse the OPS Peptide Science catalog for verified research-grade TB-500.

TB-500 (thymosin beta-4) stands out among research peptides for its mechanistic clarity, its broad tissue-repair research applications, and its strong pairing with BPC-157 in combination protocols. For researchers studying tissue repair, cell migration, cardiac biology, or dermal endpoints, TB-500 is one of the most-cited compounds in the modern research catalog.

For research-grade TB-500 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Peptide Education, Product Pillars, Research Protocols

BPC-157: Complete Research Guide to the Body Protection Compound Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: BPC-157 is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

BPC-157 — short for Body Protection Compound-157 — is one of the most extensively studied research peptides in modern compound science. A 15-amino-acid synthetic peptide originally identified in gastric juice, BPC-157 has been the focus of hundreds of published animal and in-vitro studies investigating tissue repair, anti-inflammatory effects, and signaling pathway modulation. This complete guide from the chemistry team at OPS Peptide Science walks through what BPC-157 is, what the research literature documents, how researchers handle it in protocols, and where it sits in the broader peptide research catalog.

For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is BPC-157?

BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence originally identified in human gastric juice. The name “Body Protection Compound” reflects the research history — BPC-157 was first studied in gastrointestinal protection contexts before researchers documented its broader effects across tissue types.

Key facts about BPC-157:

Chemical class — short peptide (15 amino acids), synthetic version of a naturally occurring gastric sequence
Molecular weight — approximately 1419 Da
Sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (single-letter: GEPPPGKPADDAGLV)
Form — typically supplied as lyophilized (freeze-dried) powder; reconstituted with bacteriostatic water for research administration
Half-life — short, approximately 4-6 hours in research models
Stability — stable at -20°C as lyophilized powder for 18-24 months; reconstituted solutions stable for 21-28 days refrigerated

BPC-157 is one of the most-searched research peptides because the published literature is substantial — hundreds of animal studies and in-vitro experiments document effects across multiple research models. The compound is not FDA-approved and is sold legally in the US only as a research chemical under research-use-only labeling.

BPC-157 Structure and Chemistry

The BPC-157 sequence is unusual for a research peptide. Most synthetic peptides are designed analogs of larger hormones (insulin fragments, growth hormone secretagogues). BPC-157 instead originates from the protein BPC (Body Protection Compound) found in gastric juice. The “157” in its name refers to the partial sequence position from the parent BPC protein.

Structurally significant features:

High proline content — five proline residues (positions 3, 4, 5, 8) give the peptide structural rigidity and unusual resistance to enzymatic degradation
Gastric origin — the parent protein evolved to function in the stomach environment, giving BPC-157 unusual stability under acidic and enzymatic conditions
Stable in gastric environment — published research has documented some oral bioavailability for BPC-157 due to this gastric stability, though most research protocols use injection administration

This proline-rich sequence is part of why BPC-157 became such an active research compound — its stability profile is unusually favorable for a small peptide, allowing reliable research dosing protocols.

How BPC-157 Works in Research (Mechanism)

The BPC-157 mechanism is not characterized by a single receptor binding event — research has documented effects across multiple biological pathways, which is unusual for synthetic peptides and contributes to its broad research interest. Documented pathways include:

VEGF (Vascular Endothelial Growth Factor) modulation — BPC-157 has been documented to upregulate VEGF expression, which drives angiogenesis (new blood vessel formation)
Nitric oxide system interactions — research literature shows BPC-157 influences both NO synthesis and the NO system’s vasodilation effects
Growth hormone receptor expression — published studies have documented increased growth hormone receptor expression in tendon and other tissue research models
Inflammatory pathway modulation — measured reductions in pro-inflammatory cytokines (IL-6, TNF-α) in animal injury models
Dopaminergic system effects — some research literature documents effects on dopamine systems, suggesting central nervous system activity
Serotonin system effects — published animal research has measured serotonin modulation in some research models

The multi-pathway nature of the BPC-157 mechanism is what makes the compound interesting in research contexts — it doesn’t fit the typical one-receptor-one-effect model of most synthetic peptides. The BPC-157 research literature on PubMed documents these pathways across hundreds of studies, though the overall mechanistic picture remains incomplete in published literature.

BPC-157 Research Applications

Research literature documents BPC-157 effects across several major application areas:

Tendon and Ligament Research

The most extensively studied BPC-157 application is in tendon and ligament repair research. Multiple animal models — Achilles tendon transection, medial collateral ligament injury, muscle crush — have documented faster repair markers, improved tensile strength recovery, and accelerated cell migration in BPC-157-treated subjects compared to controls.

Gastrointestinal Research

BPC-157’s gastric origin gives it natural research relevance for GI applications. Published research includes ulcer healing models, inflammatory bowel disease models, and gastrointestinal barrier function studies. The compound shows measurable effects on mucosal healing markers in animal models.

Muscle and Soft Tissue Repair

Beyond tendons, BPC-157 research extends into skeletal muscle injury models, soft tissue inflammation, and post-traumatic recovery markers in animal subjects. Published studies have documented effects on muscle satellite cell activity and fiber regeneration markers.

Bone Research

Animal models of bone fracture and bone graft research have documented BPC-157 effects on bone healing markers, callus formation, and bone density endpoints. The mechanism appears to involve the VEGF angiogenesis pathway that supports bone tissue regeneration.

Neural Research

Smaller but growing research body on BPC-157 effects in neural injury models, traumatic brain injury research, and neuroprotection contexts. The dopaminergic and serotonergic system effects suggest broader CNS activity than was originally characterized.

BPC-157 Research Studies and Literature

The BPC-157 research literature spans approximately 30 years, originating primarily from research programs at the University of Zagreb (Croatia) and expanding to research groups worldwide. The published research base includes:

Hundreds of animal studies — predominantly rodent models, with smaller numbers in larger animals
In-vitro cell culture studies — fibroblast, endothelial, and muscle cell research
Pharmacokinetic characterization — half-life, distribution, and clearance data in animal models
Mechanism investigation — receptor binding studies, pathway analysis, gene expression research
Comparative studies — BPC-157 compared to other tissue-repair compounds in similar research models

Notably absent: large-scale human clinical trials. BPC-157 has not completed the FDA approval pipeline. Research remains primarily animal and in-vitro, with the compound sold in the United States only as a research chemical for laboratory study.

BPC-157 Dosing in Research Models

Research dosing of BPC-157 varies significantly across published studies. Common patterns in the literature:

Animal model dosing — typically reported in μg/kg body weight, with daily or twice-daily subcutaneous administration
In-vitro cell culture concentrations — typically reported in nM or μM in published research
Protocol duration — most published studies run 1-4 weeks of consistent dosing to capture tissue-level effects
Administration route — subcutaneous injection is the most common in published animal research, with some studies using intramuscular or oral administration

Research protocols should always reference published methodology for the specific research model. The optimal dosing varies by animal species, research endpoint, and specific injury or condition being studied. For practical research-workflow setup, see our guide on what size syringe for peptides for the standard equipment used in subcutaneous BPC-157 administration.

BPC-157 Storage and Stability

BPC-157 stability profile is among the more favorable for small research peptides, owing to its proline-rich structure:

Storage Condition	Form	Stability Window
-80°C (ultra-low freezer)	Lyophilized powder	3-5+ years
-20°C (standard lab freezer)	Lyophilized powder	18-24 months
2-8°C (refrigerated)	Lyophilized powder	6-12 months
Room temperature	Lyophilized powder	2-4 weeks for transit
2-8°C (refrigerated)	Reconstituted in BAC water	21-28 days

For detailed stability and storage protocols, see our guide on how long do peptides last at room temperature.

BPC-157 + TB-500 Combination Research (Wolverine Stack)

One of the most-discussed BPC-157 research applications is its combination with TB-500 (Thymosin Beta-4) — popularly called the “Wolverine Stack” in research and biohacking discussions. The rationale for combination research:

Different mechanisms — BPC-157 acts on VEGF/angiogenesis pathways; TB-500 acts on actin/cell migration
Potentially additive effects — the two pathways could combine without overlapping, producing additive tissue-repair effects
Documented in published research — both compounds appear in combination protocols across animal research studies

Research design for combination studies requires separate reconstitution, separate injection sites, and careful documentation of each compound’s contribution. See our companion overview on peptides for healing and recovery for the broader context on these compounds.

How to Identify Quality BPC-157

The research peptide market includes vendors of varying quality. Quality BPC-157 research-grade peptide has these characteristics:

99%+ purity confirmed by HPLC-MS analysis — purity below this level can compromise research data through unknown contaminants
Per-lot Certificate of Analysis — each batch independently tested and documented, not just a generic spec sheet
Documented mass spectrometry identity — confirms the compound is actually BPC-157 and not a degradation product or contaminant
Chain-of-custody documentation — traceable from manufacturer to fulfillment
Properly lyophilized appearance — should be a clean white cake at the bottom of the vial, not discolored or melted
Research-use-only labeling — required by US regulations for non-FDA-approved compounds

At OPS Peptide Science, every BPC-157 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot before opening the vial — a key trust signal that distinguishes documented research-grade compound from unverified market peptides.

BPC-157 Regulatory Status

BPC-157 occupies a specific position in US regulatory frameworks:

Not FDA-approved — has not completed clinical trials required for human drug approval
Removed from 503A compounding list in 2023 — pharmacies can no longer compound BPC-157 for prescription use
Added to WADA Prohibited List in 2023 — banned in WADA-governed athletic competition under category S0
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not DEA-scheduled — no controlled substance status

For the complete legal framework around peptides like BPC-157, see our detailed guide on are peptides illegal. According to NIH research literature, BPC-157 remains an active area of pre-clinical investigation despite the regulatory restrictions on human use.

FAQ

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a sequence originally identified in gastric juice. It is one of the most extensively studied research peptides, with hundreds of animal and in-vitro studies documenting effects on tissue repair, angiogenesis, anti-inflammatory pathways, and gastrointestinal research models.

Is BPC-157 legal in the US?

BPC-157 is legally sold in the US as a research chemical for in-vitro and animal study, under research-use-only labeling. It is not FDA-approved for human use and was removed from the 503A pharmacy compounding list in 2023. WADA has prohibited it in athletic competition since 2023.

How long does BPC-157 take to work in research?

Research timeline varies by endpoint and model. Acute anti-inflammatory effects appear within days in animal research models. Tissue-level repair effects (tendon, ligament, muscle healing) typically require 2-4 weeks of consistent dosing. Specific timelines depend on the injury model and the research endpoint being measured.

Can BPC-157 be taken orally in research?

Research literature documents some oral activity for BPC-157 due to its gastric-protein origin and proline-rich structure, which resists digestive degradation better than most peptides. However, most published research protocols use subcutaneous injection because injection bioavailability is more reliable and reproducible than oral.

What’s the difference between BPC-157 and TB-500?

Both are research peptides studied in tissue-repair contexts, but they act through different mechanisms. BPC-157 acts on VEGF/angiogenesis and multiple signaling pathways. TB-500 (Thymosin Beta-4) acts on actin sequestration and cell migration. Combination research (the “Wolverine Stack”) explores whether the two produce additive effects.

How do I store BPC-157?

Lyophilized BPC-157 powder stores at -20°C for 18-24 months. Reconstituted BPC-157 in bacteriostatic water stores at 2-8°C for 21-28 days. See our complete guide on peptide refrigeration requirements for detailed storage protocols.

Where can I buy research-grade BPC-157?

Research-grade BPC-157 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, and traceable chain-of-custody documentation. Browse the OPS Peptide Science catalog for verified research-grade BPC-157.

BPC-157 occupies a unique position in modern research peptide science — a small synthetic peptide with a substantial published literature base, an unusually favorable stability profile, and documented effects across multiple research applications. For researchers studying tissue repair, gastrointestinal models, or related endpoints, BPC-157 remains one of the most-referenced compounds in the modern research catalog.

For research-grade BPC-157 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026